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Factor Va Directs Catalysis by Factor Xa During Prothrombin
Activation
MICHAEL A. BUKYS
Abstract
Hemostasis occurs through the controlled activation and inactivation of clotting
factors resulting in the arrest of bleeding without blockage to the vasculature, while
thrombosis is the undesired formation of vascular blood clots, which adversely affects
millions of people annually. Clotting factors circulate in blood as inactive zymogens,
which are proteolytically activated in response to vascular injury, assembled into
enzymatic complexes and in turn activate additional coagulation factors culminating in
the production of thrombin from the enzymatic complex prothrombinase. The
prothrombinase complex is composed of the activated enzymatic component factor Xa
(fXa) complexed to the activated cofactor portion factor Va (fVa) assembled on a
membrane surface in the presence of calcium. Prothrombinase enzymatic activity results
in the conversion of prothrombin, the inactive precursor, to thrombin, the active enzyme
following two sequential proteolytic cleavages. Thrombin in turn converts fibrinogen, a
soluble precursor, to fibrin, the insoluble product which composes the meshwork of a
fibrin clot. Therefore, the regulation of prothrombinase will result in the inhibition of clot
formation.
Incorporation of fVa into the prothrombinase complex increases the catalytic rate of
fXa by five orders of magnitude and increasing kinetic studies have suggested that
prothrombinase has two equilibrating forms which function in conjunction in the
production of thrombin. The prothrombinase complex is unique in its function of
iv

activating thrombin making it the ideal enzyme to target for regulating thrombin
production, however the molecular events governing prothrombinase assembly and
function are not well understood, and a better understanding of these events will provide
novel targets for therapeutic compounds capable of regulating thrombin production. The
long-term goal of this study is to determine the molecular interactions governing
prothrombinase assembly/function, because the specific inhibition of thrombin formation
will be realized through the disruption of prothrombinase assembly. Our central
hypothesis is that discrete amino acid binding motifs present on fVa for the components
of prothrombinase represent a potential source of anticoagulant molecules. Thus, defining
binding regions present on fVa for fXa and or prothrombin is necessary in the
development of specific inhibitors of prothrombinase that could be used in treatment of
individuals with thrombotic tendencies. This proposal plans to define regions present in
fVa to target disruption of prothrombinase assembly by addressing the following specific
aims.
Specific Aim 1: Determine the relative contribution of the binding of fVa’s heavy
chain to fXa in the overall function of prothrombinase.
Specific Aim 2: Determine the role of the carboxyl-terminal portion of the heavy
chain of fVa in prothrombinase catalyzed activation of prothrombin.
Specific Aim 3: Determine the discrete amino acid residue(s)/region(s) present in the
light chain of fVa which are involved in the recognition of fXa.
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CHAPTER I
INTRODUCTION
One of the most important systems within the human body is the vasculature,
because all organs and tissues are dependent on it for survival. Blood transports all of the
nutrients and removes all of the metabolic wastes from the tissues of the body. Therefore
maintenance of the vascular system, termed hemostasis, is vital for survival. Hemostasis
is the controlled arrest of bleeding and maintains vessel integrity with minimal blood loss.
Hemostasis ensures the balance between the opposing undesired conditions of thrombosis
and hemophilia. Thrombosis is the unneeded formation of a clot within the vasculature
and can result in deep vein thrombosis (DVT), pulmonary embolism, stroke or heart
attack (1). Hemophilia is uncontrolled bleeding and results in severe blood loss. Both
thrombosis and hemophilia have contributing genetic components as well as acquired
causes and better treatment methods are needed for both of these conditions.
The entire vasculature is lined with a single layer of endothelial cells which form
the walls of the vessels and veins which normally function as an anticoagulant surface
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ensuring no blockage to the vasculature occurs (2). An injury occurs when the endothelial
lining of the vasculature is disrupted allowing the circulating blood to leak outside of the
vasculature resulting in the blood being exposed to the sub-endothelial environment. The
sub-endothelial environment has many procoagulant components within it which function
to promote clot formation (3). Of these procoagulant factors collagen and the protein
tissue factor are essential. Exposure of the blood to collagen results in the activation of
platelets and exposure of the blood to tissue factor initiates the coagulation response (4,5).
An injury to the vasculature triggers many other responses all of which result in blockage
of the injured site as a means to minimize blood loss. The combination of all of these
responses is termed hemostasis and is divided into two interconnecting processes termed
primary and secondary hemostasis.
1.1 PRIMARY HEMOSTASIS
The initial response to vascular injury is termed primary hemostasis. Primary
hemostasis involves two interrelated processes; first a narrowing of the injured vessel
minimizes blood flow to the damaged area while the formation of an initial platelet plug
seals the injured site (6). Vasoconstriction is the first response to an injury that occurs in
a damaged blood vessel and is a narrowing of the vessel to restrict blood flow to the
injured area resulting in a minimization of blood loss. Exposure of blood to the subendothelial environment causes platelets to adhere at the injured site resulting in the
formation of a primary platelet plug. Exposure of platelets to the collagen present in the
sub-endothelial environment stimulates the activation of platelets (7).
Activated platelets release the contents from their interior alpha and dense granules
resulting in the secretion of the vasoconstrictors serotonin, prostaglandin and

2

thromboxane (8). An enzymatic flipping of inner leaflet phosphatidylserine phospholipids
to the outer leaflet upon activation of platelets creates an enzymatic surface capable of
sustaining the formation of enzymatic complexes composed of coagulation factors which
are attracted to the negatively charged surface (9,10). The activation of platelets also
results in the release of many molecules from within the platelet needed for clot
formation, including fibrinogen, factor V and von Willebrand factor (11). All subendothelial tissues express the cellular membrane protein tissue factor which is exposed
to the circulation when the endothelial layer is disrupted. The exposure of tissue factor to
the circulation is the initiating event in the coagulation portion of hemostasis, termed
secondary hemostasis (9,10). The initial platelet plug is a temporary blockage to the site
of injury and is strengthened by the deposition of fibrin, the end product of the
coagulation cascade. The polymerization of fibrin leads to the stabilization of the platelet
plug needed to ensure hemostasis.
1.2 COAGULATION RESPONSE
Secondary hemostasis is also referred to as the coagulation cascade and culminates in
the formation of fibrin deposition upon the initial platelet plug resulting in a stabile
blockage to the injured site (12, 13). Platelets are actively involved in the coagulation
response known as secondary hemostasis because they generate the negatively charged
catalytic surface needed for formation of all enzymatic complexes (3). The coagulation
cascade is composed of the sequential activation of clotting factors culminating in the
production of fibrin from the zymogen fibrinogen. Coagulation enzymes are serine
proteases with highly specific substrate recognition determined by exosites distant from
their active sites (14). Coagulation factors circulate in inactive forms that are
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proteolytically activated in response to vascular injuries. Activated clotting factors
assemble into sequential enzymatic complexes on the membrane surfaces provided by
activated platelets (9,10,15). The association between activated membrane surfaces and
the components of the enzymatic complexes are dependent on Gla domains. Gla domains
are regions present within the proteins that have several gamma carboxylated glutamic
acid residues (16). The gamma carboxylation of glutamic acid residues are vitamin K
dependent post-translational modifications necessary for protease recognition of the
membrane surface.
The initiating event in the coagulation cascade is the exposure of tissue factor to the
circulation resulting in the formation of the extrinsic Xase complex (17). A small fraction
of fVII circulates in an active form and will complex with tissue factor when it is exposed
to the blood (9). The extrinsic Xase complex is formed when circulating factor VIIa
comes in contact with tissue factor. The extrinsic Xase complex recognizes the substrates
factor IX and factor X proteolytically converting them to their active forms factor IXa
(fIXa) and factor Xa (fXa), respectively (18). However the extrinsic Xase complex
recognizes the substrate fIX with a much higher affinity than it recognizes fX and
consequently the production of fIXa is necessary, needed for formation of the intrinsic
Xase complex, is necessary for efficient production of fXa.
The intrinsic Xase complex is formed when the enzymatic component fIXa, generated
from the extrinsic Xase complex, comes in contact with its activated cofactor portion,
factor VIIIa, on a catalytic surface provided by activated platelets (19). The importance
of the intrinsic Xase complex in proper fibrin formation is demonstrated by the genetic
disorder hemophilia which occurs in individuals missing the gene for fVIII. The intrinsic
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Xase complex recognizes the substrate fX, with a far greater specificity than the extrinsic
Xase complex and is thus obligatory for sufficient generation of the active form of fX and
consequently normal fibrin formation. Formation of the intrinsic Xase complex results in
the rapid generation of fXa, the enzymatic component of the prothrombinase complex
which is responsible for the activation of prothrombin to its active form thrombin.
The prothrombinase complex is composed of the activated enzymatic component, fXa,
associated with the activated cofactor portion, factor Va (fVa), on a catalytic surface
supplied by activated platelets in the presence of calcium ions (20,21). Prothrombinase
proteolytically activates prothrombin through two sequential activating cleavages at
Arg320 and Arg271 to produce the enzyme product, thrombin. Thrombin is responsible for
the conversion of fibrinogen, the soluble precursor, to fibrin the insoluble monomer
which composes the meshwork that stabilizes the fibrin clot.
1.3 THROMBIN REGULATES ITS OWN PRODUCTION
Thrombin recognizes its substrates through exosites, these are regions exposed to
plasma in the activate form of thrombin which are composed of extended basic amino
acid residues that facilitate substrate recognition (22,23). Thrombin has several substrates
which are recognized by its two anion binding exosites referred to as ABE I and ABE II.
Thrombin interacts with the substrates thrombomodulin, fibrinogen, heparin cofactor II,
PAR1, and the hirudin peptides through ABE I, while ABE II is involved in the
recognition by thrombin with the substrates heparin cofactor II, protease nexin and
antithrombin III. Both ABE I and ABE II have been implicated in interacting with the
cofactors for the intrinsic Xase complex and the prothrombinase complex, fV and fVIII
respectively (24).
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The initial production of thrombin up-regulates thrombin production by activating
the cofactors needed for the intrinsic Xase and the prothrombinase complexes, fVIII and
fV respectively (25-27). The proteolytic activation of these zymogen cofactors by
thrombin results in greatly increasing thrombin production, because the active cofactors
greatly up-regulates the activity of the intrinsic Xase and the prothrombinase complexes.
The increased fVIII generated for the intrinsic Xase complex results in a greatly
increased fXa production coupled with a greatly increased fVa production produces a
surge in the concentration of the prothrombinase complex and consequently greatly
accelerates thrombin generation. Thrombin is the enzyme responsible for the conversion
of fibrinogen, the inactive soluble zymogen, to fibrin, the insoluble meshwork of the
fibrin clot. Once formed fibrin is attracted to the platelet plug mediated through platelet
receptors and polymerizes resulting in the strengthen platelet plug. An additional way
that thrombin is responsible for greatly accelerating a fibrin clot formation is by the
activation of factor XIII. The active form of fVIII, fXIIIa, functions in cross linking the
fibrin monomers that are deposited on the platelet plug as an additional way of stabilizing
the fibrin clot (9).
The fact that thrombin also down-regulates the coagulation response by the
proteolytic activation of protein C (PC) shows the tight regulation of the coagulation
cascade. The active form of protein C (APC) is involved in down regulating thrombin
production by the enzymatic degradation of the cofactors involved in the intrinsic Xase
and prothrombinase complexes, fVIIIa and fVa respectively (28). As thrombin is
generated it will complex with thrombomodulin, a protein present on the surface of the
endothelial lining of the vasculature, resulting in the formation of the APCase enzymatic
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complex (29,30). The APCase complex is responsible for the activation of PC. Once
generated APC down regulates thrombin production through the proteolytic degradation
of fVIIIa through three sequential cleavages at Arg336, Arg562 and Arg740 resulting in the
loss of the intrinsic Xase complex ability to generate fXa. The enzymatic degradation of
fVa is also mediated by APC through three sequential proteolytic cleavages of fVa at
Arg506, Arg306, and Arg679 destroying the affinity of fVa for the prothrombinase complex.
1.4 PROTHROMBINASE REGULATES THROMBIN PRODUCTION
As previously described coagulation occurs by a series of limited enzymatic
cleavages

of

sequential clotting factors calumniating in the formation of the

prothrombinase complex (20,21). Both the intrinsic and extrinsic pathways lead to the
formation of the prothrombinase complex, also known as the common pathway because
of its central role in thrombin production. Prothrombinase is unique in its function of
activating prothrombin to generate thrombin. The prothrombinase complex consists of an
assembly of activated clotting factor X (fXa) and activated clotting factor V (fVa) on a
platelet surface in the presence of calcium ions (20,21). Factor Xa is the enzymatic
portion of prothrombinase and is capable of catalyzing prothrombin activation by initially
cleaving Arg271 producing the two inactive intermediates, prethrombin 2 (residues 272579), and fragment 1·2 (residues 1-271) (31). Prethrombin 2 is sequentially cleaved by
membrane-bound fXa at Arg320 to produce thrombin. This process proceeds through
inactive intermediates and has an overall reaction rate insufficient for timely thrombin
production.
The association of fVa with fXa in the prothrombinase complex causes a reversal of
the observed cleavage pattern of prothrombin in addition to a 300,000 fold increase in the
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Figure 1.1
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Figure 1.1 – The activation of prothrombin. Pathway 1 - Membrane-bound fXa
catalyzes prothrombin activation by initially cleaving at Arg271 producing the inactive
intermediate prethrombin 2 and fragment 1·2. Prethrombin 2 is then sequentially
cleaved at Arg320 to produce thrombin and fragment 1·2. Pathway 2 – In the presence
of a fully assembled prothrombinase complex the rate of thrombin generation is
greatly enhanced and the order of the prothrombin activating cleavages are reversed.
Prothrombinase initially cleaves prothrombin at Arg320 generating the active
enzymatic intermediate, meizothrombin. Meizothrombin is then cleaved at Arg271 to
produce thrombin and fragment 1·2.
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rate of thrombin production. Prothrombinase catalyzed activation of prothrombin
proceeds through initially cleaving prothrombin after Arg320, producing meizothrombin
(residues 1-320 covalently attached through disulfide linkage to residues 321-579), an
enzymatic active intermediate (32). Prothrombinase rapidly consumes the meizothrombin
intermediate by catalyzing the additional activating cleavage at Arg271 producing
thrombin and fragment 1·2 (33,34). In addition to the greatly accelerated rate of thrombin
generation realized through prothrombinase as compared to membrane-bound fXa, the
enzymatic intermediate meizothrombin is capable of activating additional clotting factors.
1.5 FACTOR

Va

INTERACTS

WITH

ALL

COMPONENTS

OF

PROTHROMBINASE
The physiological importance of fVa is demonstrated by the increased cases of DVT
attributed to a single point mutation in its gene and the fact that its loss results in severe
hemophilia. The zymogen factor V (fV) has a MW of 330,000kDa and circulates through
plasma at a concentration of 20nM. FV is composed of three homologous A domains; the
A1 domain composed of residues 1-303, the A2 domain composed of residues 317-656
and the A3 domain composed of residues 1546-1877, an interconnecting B region
composed of residues 710-1545 and two C domains; the C1 domain composed of
residues 1878-2036 and the C2 domain composed of residues 2037-2196 (35). The
zymogen fV has the domain composition of A1-A2-B-C1-C2-A3 and zymogen activation
is realized through the removal of the interconnecting B-domain from the rest of the
molecule. Both thrombin and meizothrombin activate fV through three sequential
cleavages occurring after Arg709, Arg1018 and Arg1545 resulting in an active cofactor, fVa,
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Figure 1.2
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Figure 1.2 – The activation of the zymogen factor V occurs through three sequential
thrombin mediated cleavages occurring at Arg709, Arg1018 and Arg1545 resulting in the
active form of the cofactor composed of a heavy chain derived from the carboxylterminal portion and a light chain derived from the amino-terminal portion. The
heavy chain is composed of residues 1-709 while the light chain is composed of
residues 1546-2196 and the two chains are associated with each other through
calcium ions.
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composed of an amino-terminal derived heavy chain (residues 1-709) of Mr 105,000kDa
and a carboxyl-terminal derived light chain (1546-2196) of a Mr of 74,000kDa. The
association of the heavy and light chains of fVa is non-covalent and dependent on the
presence of Ca2+ ions (36).
Both the heavy and light chains of fVa are needed in binding the components of the
prothrombinase complex. The heavy chain of fVa interacts with prothrombin through an
acidic region present at the carboxyl-terminal portion (37,38). The heavy chain of fVa is
also involved in recognition of fXa through residues present within the A2 domain at
positions 323-331 (39,40). It has been demonstrated that the light chain of the cofactor
binds both the membrane surface and fXa. The recognition of the membrane surface by
the light chain of fVa occurs through residues present within the C2 domain and has been
thoroughly characterized (41-43). Previous studies have implicated the A3 domain of the
light chain of fVa in binding fXa, however little is known on which amino acid residues
are involved in the association (44-45).
1.6 THE INACTIVATION OF FVa
Due to the central role fVa plays in thrombin generation both the generation and
degradation of fVa is highly regulated and the existence of the active form of fV is very
transient because it is degraded shortly after it is generated. Thrombin not only upregulates fVa production, but starts the down regulation of fVa by activating protein C
(PC) the serine protease responsible for the enzymatic degradation of fVa (46). PC
circulates in plasma at a concentration of 60nM and is activated by an enzymatic complex
composed of thrombin and thrombomodulin (47). The activation of PC occurs through a
single proteolytic cleavage occurring at Arg169 to produce the active form, APC. APC
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down regulates thrombin production by inactivating the cofactor fVa through three
sequential cleavages occurring at Arg506, Arg306 and Arg679 (28).
The importance of APC for the down regulation of thrombin production is
illustrated through the commonly occurring fVLEIDEN mutation. The fVLEIDEN mutation
has been correlated to an increased occurrence of DVT and results from a single point
mutation in the gene encoding fV which causes a R506Q substitution in the protein (48).
This substitution removes the APC mediated cleavage site within the A2 domain of fVa
and consequently decreases the rate of APC mediated inactivation of fVa 10-fold (49).
Increased occurrence of DVT is associated with the decreased ability of APC to degrade
the active form of the fVLEIDEN mutation.
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CHAPTER II
INCORPORATION OF FACTOR Va INTO PROTHROMBINASE IS REQUIRED
FOR COORDINATED CLEAVAGE OF PROTHROMBIN BY FACTOR Xa
2.1 ABSTRACT
The interaction of fXa with fVa promotes prothrombinase assembly and is governed
by two distinct regions within fVa. It has been demonstrated on several occasions that
one important region governing the fXa/fVa interaction and proper prothrombinase
assembly is present within the A2 domain of the heavy chain of fVa. We have used
overlapping synthetic peptides representative of residues 307-348 of the A2 domain to
screen their ability to inhibit prothrombinase activity in a fXa dependent manner. Peptide
studies indicated amino acid residues 323, 324, 330 and 331 of the A2 domain are crucial
for fVa recognition of fXa. The present study employs recombinant mutations within
these residues consisting of 323DY324  323FF324 (fVaFF), 330DV331  330MI331 (fVaMI) and
the combined mutation of

323

DY324 and

330

DV331 

323

FF324 and

330

MI331 (fVaFF/MI). All

recombinant molecules were assayed for their ability to accelerate fibrin clot formation in
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clotting based assays. Kinetic studies determined Kd values for the fVa/fXa interaction
showing an approximate 4-5 fold decrease for the ability of fXa to interact with rfVaFF
and rfVaMI and an approximate 50-fold decrease in the ability of fXa to interact with the
rfVaFF/MI mutant. Determined Kcat values generated for prothrombinase catalyzed
reactions performed with fXa fully saturated with the rfVaMI and rfVaFF mutants
demonstrated values comparable to rfVaWT. While prothrombinase assembled with the
combined rfVaFF/MI mutant demonstrated a severely decreased Kcat value when
compared to rfVaWT. The present study demonstrated drastic changes in the kinetic
parameters governing prothrombinase assembled with the rfVaFF/MI molecule
demonstrating the effects the loss of the fXa/fVa interaction has on the normal function
of prothrombinase.
2.2 INTRODUCTION
The arrest of bleeding is dependent on the generation of thrombin from the
enzymatic complex prothrombinase (1-3). Though the enzymatic component of
prothrombinase, activated factor X (fXa) is capable of activating the zymogen
prothrombin, the rate of this reaction is insufficient for timely thrombin generation in
response to vascular injury. The incorporation of activated factor V (fVa) into the
prothrombinase complex accelerates the rate of thrombin generation by five orders of
magnitude, as well as reverses the order of the two activating cleavages that occur within
prothrombin (3,4). It has been well-established that membrane-bound fXa initially
cleaves prothrombin at Arg271 resulting in a non-enzymatic intermediate, prethrombin 2
(residues 271-579 of prothrombin) which is then subsequently cleaved at Arg320 to
generate thrombin (4). The association of fXa with fVa, results in a reversal of these two
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proteolytic events with initial prothrombin cleavage occurring at Arg320 followed by
cleavage at Arg271 (3,5) This latter pathway to thrombin generation has an enzymatic
intermediate, meizothrombin, and occurs at a greatly accelerated rate (6).
The zymogen factor V (fV) circulates in plasma at a concentration 20nM and has
no cofactor effect before proteolytic processing resulting in the formation of the active
form of fV. Both thrombin and fXa are capable of activating fV through three sequential
cleavages occurring at Arg709, Arg1018 and Arg1545 generating an amino-terminally
derived heavy chain composed of two homologous A domains (A1-A2), a carboxylterminally derived light chain composed of an A domain followed by two C domains
(A3-C1-C2) and the release of the interconnecting B domain (7,8). The association of the
heavy and light chains of fVa is calcium dependent and necessary for the generation of a
functional cofactor (9). The association of fVa with fXa is highly specific with a Kd of
approximately 0.2nM and has been shown to be mediated through two distinct regions
present within the A2 and A3 domains of fVa (9).
Experimental evidence for the A2 domain’s involvement in recognition of fXa
has been demonstrated by many research groups. Experiments employing activated
protein C (APC), an anticoagulant molecule which degrades the heavy chain of fVa,
correlates the loss of the cofactor effect to the removal of the A2 domain from fVa
(10,11). APC degrades fVa through three consecutive cleavages occurring within the
heavy chain of fVa at Arg506, Arg306 and Arg679 and completely inactivates the cofactor.
Peptide studies of the A2 domain have shown that N42R (a synthetic peptide designed
with the corresponding sequence from amino acid residues 307-348 of the heavy chain of
fVa) is capable of mimicking the loss of function associated with APC degradation of
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fVa by strongly inhibiting prothrombinase activity in a fXa dependent manner (11).
Further peptide studies have indicated that residues 323-324 and 330-331 from fVa are
involved in binding fXa and are required for optimal cofactor effect for the
prothrombinase catalyzed activation of prothrombin (12,13). The present recombinant
study was undertaken to identify the contribution of these residues to the overall function
of the prothrombinase molecule.
2.3 EXPERIMENTAL PROCEDURES
Materials, Reagents and Proteins. L--phosphatidylserine (PS) and L-phosphatidylcholine (PC) were purchased from Avanti Polar Lipids (Alabaster, AL) and
prepared as previously described (14) and quantified by assaying for phosphorus. The
chromogenic substrate Spectrozyme-TH was purchased from America Diagnostica, Inc
(Greenwich, CT). Human -thrombin, prothrombin, human fXa and the fluorescent
thrombin

inhibitor

dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide

(Dapa)

were

purchased from Hematologic Technologies, Inc. (Essex Junction, VT). The monoclonal
antibody hFV1 coupled to Sepharose, and the two monoclonal antibodies against factor
V (against the heavy and the light chains respectively, HFVHC#17 and HFVLC#9) were
provided by Dr. Kenneth G. Mann (Department of Biochemistry, University of Vermont,
Burlington,

VT).

Diisopropyl

fluorophosphates

(DFP),

O-phenylenediamine

dihydrochloride (OPD), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
Trizma, Coomassie Blue R-250 and factor V-deficient plasma were purchased from
Sigma. Polyethylene glycol (Mr 8000) was purchased from J. T. Baker (Danvers MA).
The secondary anti-mouse and anti-sheep IgG coupled to peroxidase were purchased
from Southern Biotechnology Associates Inc. (Birmingham, AL). The chemiluminescent
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reagent ECL+ was purchased from Amersham Biosciences. The thromboplastin reagent
(recomboplastin) used in clotting assays was purchased from Beckman (Fullerton, CA).
The cDNA encoding fV was purchased from American Type Tissue Collection (ATCC
40515 pMT2-V, Manassas, VA). All restriction Enzymes were purchased from New
England Biolabs (Beverly, MA). Human fV and fVa were purified and concentrated
using methodologies previously described employing the monoclonal antibody hFV#1
coupled to sepharose and heparin-sepharose respectively (11,15,16).
Generation of Recombinant Mutations. The recombinant fV mutations used
throughout this series of experiments were generated using PCR based mutagenesis. The
heavy

chain

mutations

were

generated

GAAGAGGTGGTTCTTCTTCATTGCTGC-3'

using
(sense)

the

primers
and

5'5'-

GCAGCAATGAAGAAGGAACCACCTCTTGCTGC-3' (antisense) for the rfVaFF
mutation, the primers 5'-CATTGCTGCAGAGATGATCATTTGGGACTATGC-3' (sense)
and 5'-GCATAGTCCCAAATGATCATCTCTGCAGCAATG-3' (antisense) were used
to generate the rfVaMI mutation (the underlined portion of the primers are the mismatched
bases). PCR reactions were performed in the presence of outer primers encompassing the
upstream XcmI restriction site (5'-ACATCCACTACCGCAATATGAC-3') and the down
stream Bsu361 site (5'-CCTCAGGCAGGAACAACACCATGA-3'). PCR products were
purified from agarose gels and subjected to a third PCR reaction performed in the
presence of the purified products. The product from the third PCR reaction and pMT2-fV
were both subjected to XcmI and Bsu361 digestion followed by a ligation reaction to
insert the desired mutations. Ligation products were transformed into chemically
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competent bacteria cells and colonies were screened for the presence of the desired insert
through DNA sequencing.
Generation of Recombinant Proteins. All of the respective mutagenic plasmids
were transiently transformed into Cos 7 cells using the transformation reagent fugene 6.
Cos 7 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 100
g/ml streptomycin, 100 IU/ml penicillin and incubated at 37°C in the presence of 5%
CO2 atmosphere. Transfection was performed on plates approximately 70% confluent by
the addition of 2 g of fugene 6 treated DNA per plate. Plates of transfected Cos 7 cells
were incubated for 48 hours before being washed twice with a phosphate buffered saline
solution followed by incubation in the presence of VP-SFM medium supplemented with
5mM L-glutamine. Harvesting of the cultured VP-SFM medium was performed for 4
consecutive 24 hour intervals and either concentrated or frozen for future use.
Quantification of Recombinant fV Molecules within the Harvested Medium.
Harvested medium from the transfected Cos 7 cells were concentrated by centrifugation
on YM-30 centricons to a final volume of approximately 1 ml followed by three
consecutive washes with trizma buffered saline solution containing 5mM CaCl2. ELISA
specific for fV was performed on the washed concentrated medium containing the fV
heavy chain mutants. Briefly, 96-well plates were coated with a polyclonal anti-fV
antibody diluted in a carbonate buffer and incubated overnight at 4°C, ELISA plates were
then washed three times with a trizma buffered saline (TBS) solution containing 5%
tween 80 followed by an hour incubation at 37°C in the presence of 5% milk diluted in
TBS + 5% tween 80. Serial dilution of the concentrated harvested medium containing the
respective rfV heavy chain mutants were incubated along side a plasma derived fV serial
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dilutions performed in triplicate with concentrations ranging from 0.01g to 10g as a
standard. The monoclonal anti-human fV antibody, -hfV#17, was incubated on the
washed ELISA plate at a concentration of 5g/ml for an hour at 37°C followed by an
additional hour incubation of the ELISA plate in a 1:2000 dilution of a secondary antimouse coupled with HRP antibody. ELISA plates were developed using OPD (5mg)
tablets dissolved in 12ml 0.1M citric acid and 0.1M Na2HPO4 for 15 minutes before the
addition of 150l of 2.5M H2SO4 to stop the reaction. The standard was graphed as log of
the concentration of the plasma derived fV vs. the absorbance at 490nm. The absorbance
of the serial dilutions of the concentrated medium was compared to that of the standard
for the determination of the concentration of the respective rfV molecules.
Activation of Recombinant Molecules. Throughout the research, activation of the
respective recombinant molecules was accomplished by incubating the molecules with
thrombin at a 1/100 (enzyme to substrate) ratio for ten minutes at 37°C. Addition of 2mM
DFP, a specific serine protease inhibitor, was performed to stop the activation reaction
followed by 10 minute incubation on ice before use. Experiments showed that these
conditions assured complete activation of the cofactor with minimal thrombin
degradation of the activated molecule. However, for all protein preparations western blots
using monospecific antibodies recognizing the heavy and light chains of fVa respectively
was performed to confirm the generation of the active cofactor.
Assaying the Activity of the Recombinant Molecules. Equivalent concentrations of
activated recombinant proteins were used in a discontinuous assay measuring thrombin
production monitored through chromogenic substrate. Reaction mixtures were composed
of 1.4M prothrombin being activated by 5nM fXa in the presence of 0.5nM fVa species,
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5M Dapa, 10M PCPS in a HEPES buffered saline solution containing 5mM CaCl2 at a
pH of 7.40. Reactions were initiated by the addition of prothrombin and aliquots of the
reaction mixture were removed at various time points during the first 5 minutes of the
reaction and quenched in a two-fold volume of a HEPES buffer containing EDTA within
a 96-well plate. Plates were then incubated with a final concentration of 0.4mM
chromogenic substrate, Spectrozyme TH, for 15 minutes before optical density readings
were taken at 405nm. Control reactions performed in the absence of fVa and with plasma
derived fVa were performed to establish minimal and optimal parameters for this series
of experiments. The reactions employing the recombinant proteins fVaWT, fVaFF, fVaMI
and fVaFF/MI were performed simultaneously with the control reactions to demonstrate
that any decrease in prothrombinase activity was due to the mutations present in the
fVaFF, fVaMI and fVaFF/MI molecules. Reactions with increased concentrations of fVaFF,
fVaMI and fVaFF/MI molecules were performed to determine if normal prothrombinase
function could be restored using higher concentrations of the respective recombinant
mutant molecules. All reactions had aliquots removed from the mixture prior to initiation
of the reaction to determine if any increase in absorption was due to the reaction mixture.
All experiments were graphed mOD verses time (seconds) using Prism graphing software.
Determination of Kinetic Parameters Governing Mutant Molecules – Assays
measuring the kinetic parameters consisted of prothrombinase assembled in the presence
of prothrombin and measured the appearance of thrombin by the secondary event of
cleavage of a chromogenic substrate. This discontinuous assay was monitored at several
time points within the first minute or two of the reaction. A limiting amount of fXa was
titrated with increasing concentrations of fVa to determine the apparent Kd value for the
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interaction. Titrations were performed in 96 well plates and measured the initial
velocities of product formation from the different concentrations of the titrant (fVa).
Time points of the different reactions were stopped by addition of EDTA. Prism graphing
software was used to graph the data and generate apparent kd values for the titrations. In
all cases mutants were compared to wild type and plasma derived fVa and measurements
were done in triplicate with different protein purifications. The obtained kd values were
used to determine proper ratios of the respective fVa mutants to fXa used in subsequent
prothrombin titration reactions ensuring similar concentrations of the assembled
prothrombinase complex were used. The degree of fXa saturation was calculated using
equation 1 (17),
[Eb] = ((i·[Tt] + [ET] + Kd) - √((i·[Tt] + [Et] + Kd)2 – 4i·[Tt]·[Et])))/2

(Eq. 1)

where Eb is the percentage of bound enzyme, i is the stoichiometry between fXa and fVa
(i.e., 1), Tt is the total concentration of the titrant (i.e., fVa), Et is the total concentration
of the enzymatic component (i.e., fXa), and Kd is the observed disassociation constant
determined from the respective fVa titration.
Prothrombin titrations were performed to determine the apparent Km and Kcat
values for the fully assembled enzymes. Prothrombin titrations were performed in 96 well
plates and reactions consisted of limiting concentrations of fXa in the presence of
saturating concentrations of fVa as determined by kd values obtained from the fVa
titrations. Prism graphing software was used to determine measurements of the initial
velocity of the varied prothrombin concentrations and used to generate a secondary graph
measuring maximum velocity and km.
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Effects of the Mutant fVa Molecules in the Activation of Prothrombin. –
Monitoring prothrombin consumption using SDS PAGE allowed for the determination of
prothrombin cleavage patterns. Prothrombinase assembled with the various fVa mutants
was used in prothrombin activating reactions monitored through SDS-PAGE followed by
coomassie blue staining. Aliquots of reaction mixtures at various time points were placed
in 0.2M acetic acid to stop the reaction followed by preparation for SDS-PAGE as
previously described (13).
Measurement of Clotting Times – One stage and two stage clotting times were
performed with all of the recombinant molecules at identical concentrations. One-stage
clotting assay consisted of addition of the procofactor (fV) into fV deficient plasma,
while two stage clotting assay consisted of the activated cofactor (fVa) being added to
fV-deficient plasma. In both cases coagulation was initiated by the addition of the
thromboplastin reagent and time to clot formation measured and transformed into specific
activity. Deficiency in mutant molecules to accelerate fibrin clot formation in fVdeficient plasma implies a functional defect. All purified protein preparations were
assayed in triplicate by this manner.
Measurement of the Interaction of the Two Mutation Sites – Since the point
mutations generated in the recombinant fVa molecules decrease the stability of the
enzymatic complex, prothrombinase, the change in the free energy of the system can be
evaluated to determine weather the two sets of mutations (i.e., rfVaMI and rfVaFF)
energetically interact (18-20). The following general equation is used to define the
change in prothrombinase function due to the mutations (state B) as compared to the wild
type fVa molecule (state A),
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GB = GB - GA (Eq. 2)
Evaluation of each of the three recombinant mutants presented in this study was
accomplished by comparison to the rfVaWT using the following equation,
GA B = - RT ln [(kcat/Km)B/( kcat/Km)A]

(Eq. 3)

where R is the universal gas constant (2 cal·K-1·mol-1), T is the temperature in Kelvin
(298K), kcat is the turnover number, and Km is the Michaelis-Menton constant for
prothrombinase assembled with the various recombinant fVa molecules. The free energy
of the interaction between two mutations can be calculated with the following general
equation,
Gint = GA B/C – (GA B + GA C)

(Eq. 4)

where the term A  B and A  C represent either of the two mutations (i.e., rfVaMI and
rfVaFF), the term A  B/C represents the double mutant (i.e., rfVaMI/FF) and the term
Gint reflects energy exchange between the individual amino acids being studied. A
Gint > 0 implies that the two mutation sites interact with each other reducing the
catalytic efficiency of the enzyme and a Gint < 0 implies that the two mutation sites
interact with each other in a fashion that enhances the catalytic efficiency of the enzyme.
2.4 RESULTS
Previous studies have indicated that binding of the heavy chain of fV to fXa
involves residues 323, 324, 330 and 331. In order to determine the contribution of these
residues to the activity of prothrombinase a recombinant study mutating these residues
was undertaken. PCR based mutagenesis was performed, as described in the method
section to generate the following mutants; rfVaFF (323DY324  323FF324), rfVaMI (330DV331


330

MI331) and the combined mutation of rfVaFF/MI (323DY324, 330DV331  323FF324,
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Figure 2.1
•

No mutation

factor Vawt

E323  F and Y324F

factor VaFF

E330  M and V331  I

factor VaMI

E323  F/Y324  F and E330  M/V331  I

factor VaFF/MI

•
•
•

Figure 2.1 – Mutations created for determination of heavy chain binding.
Previous studies using peptides representative of the heavy chain sequences of fVa
were used to determine binding regions. Recombinant proteins mutated at amino acid
residues indicated in binding of fXa were generated to further test the results
generated using synthetic peptides. The four recombinant proteins used throughout
this study were: rfVaWT (no mutations), rfVaFF (residues 323EY324  FF), rfVaMI
(residues 330EV331  MI) and the combined mutant rfVaFF/MI (323EY324  FF and
330
EV331  MI both within the same construct).
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330

MI331). Figure 1 shows a schematic outlining the mutations described above

demonstrating the sites where the mutations were introduced.
To investigate the possibility that the introduced mutations had a detrimental
effect on zymogen activation, SDS PAGE followed by Western blot was performed on all
of the recombinant mutations. Figure 2 shows Western blotting of the activated
recombinant molecules. Lane 1 is plasma derived fV that has been activated through
incubation with thrombin and serves as a control sample demonstrating the relative
positions of both the heavy and light chains of the cofactor. Lanes 3 – 6 are samples of
the recombinant molecules used throughout the study after incubation with thrombin to
generate their active forms, they are arranged rfVaWT, rfVaFF, rfVaMI and rfVaFF/MI
respectively. All of the recombinant molecules generated both heavy and light chains
following thrombin mediated activation, though there was a light chain degradation
product detected within all of them.
To assess the ability of the respective recombinant mutants to function as a
cofactor, identical concentrations of the recombinant mutants (500pM) were assembled
into a prothrombinase complex and assayed for their ability to generate thrombin. Figure
3 demonstrates that identical concentrations of plasma derived fVa (open circles) and
rfVaWT (closed circles) both accelerate the ability of fXa to generate thrombin to the same
degree showing that there is no functional defect in the wild type cofactor molecule. Both
the rfVaFF (inverse filled triangles) and the rfVaMI (filled triangles) displayed diminished
thrombin formation, though the prothrombinase assembled with rfVaMI was more
deficient in producing thrombin. Combining both mutations sites in the rfVaFF/MI,
produced a cofactor that was greatly defective in promoting thrombin production when
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Figure 2.2
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Figure 2.2 – Western Blot of Recombinant Heavy Chain Mutations. Western
blotting with two monoclonal antibodies was performed on all of the recombinant
molecules used throughout this series of experiments. Lane 1 shows activated plasma
derived fV, lane 3 shows rfVaWT, lane 4 shows rfVaFF, Lane 5 shows rfVaMI and lane 6
shows rfVaFF/MI. Arrows indicate position of the heavy and light chain of the active
cofactor as well as a low molecular weight degradation product which occurred upon
thrombin incubation of the various recombinant molecules.
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Figure 2.3
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Figure 2.3 – Activity assays comparing recombinant fVa molecules. The cofactor
activity of the various recombinant fVa molecules were assayed in the presence of 5nM
fXa as described in the experimental procedures. The various reactions shown above
are: filled circles, 500pM rfVaWT; open circles, 500pM plasma derived fVa; filled
inversed triangles, 500pM rfVaFF; filled triangles, 500pM rfVaMI; open squares, 1nM
rfVaFF/MI; open triangles, 2nM rfVaFF/MI; open inverse triangles, 5nM rfVaFF/MI; open
diamonds, 5nM fXa in the absence of cofactor; stars, 5nM fXa in the presence of
concentrated medium from plates of Cos 7 cells that were not transfected. All reactions
were performed in triplicate and error bars are representative of standard deviation.
Graphs were generated using Prisma 2.01 graphing software.

34

assembled into prothrombinase, however thrombin production was still accelerated over
lipid-bound fXa in the absence of a cofactor molecule (open diamonds). Increasing the
concentration of the rfVaFF/MI to 5nM increased the ability of prothrombinase assembled
with rfVaFF/MI (open triangles) to generate thrombin demonstrating a rate similar to that
of prothrombinase assembled in the presence of 1nM rfVaMI (filled diamonds). Since all
the recombinant molecules were assayed in concentrated medium the possibility that the
observed increased catalyst by fXa was a result of an unknown factor present in the
cultured medium had to be assayed. This possibility was assayed using an equal volume
of concentrated cultured medium from plates of Cos 7 cells that were not transfected. The
addition of the conditioned medium (stars) to a reaction mixture containing lipid-bound
fXa displayed similar capabilities for thrombin generation as that of the reaction
performed by lipid-bound fXa in the absence of fVa (open diamonds).
Since the rfVaFF, rfVaMI and rfVaFF/MI were generated to diminish fVa association
with fXa, activity assays in the presence of an increased concentration of the recombinant
cofactors were performed to determine if the impaired binding could be overcome by an
increased cofactor concentration. Figure 4 shows the results of activity assays performed
with 1nM rfVaWT, rfVaFF and rfVaMI in the presence of 5nM fXa. What we observe was
that both the rfVaFF (circles) and the rfVaMI ability to accelerate thrombin generation by
fXa increased in a fashion similar to that of 500pM rfVaWT cofactor. This demonstrates
that the weaken interaction between the recombinant mutants and fXa can be partially
compensated for by increasing the concentration of the cofactor. Since the rfVaFF/MI
combined mutations within the interactive site for fXa displays the greatest diminished
activity in assays measuring thrombin generation, the concentration of this mutant was
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Figure 2.4
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Figure 2.4 – Activity assays with increased concentrations of the recombinant fVa
molecules. Initial rates of thrombin generation were determined at ambient
temperature employing 5nM fXa in activity assays as described in the experimental
procedure section. The various reactions are: filled squares, 1nM rfVaWT; filled circles,
1nM rfVaFF; filed diamonds, 1nM rfVaMI; filled triangles, 10nM rfVaFF/MI. All
reactions were performed in triplicate and error bars are representative of standard
deviation. Graphs were generated using Prisma 2.01 graphing software.
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increased to 10nM (Diamonds) to determine if the fXa interaction could be restored.
What is observed when 10nM rfVaFF/MI is assembled into prothrombinase the ability to
accelerate the generation of thrombin is restored to a rate similar of the prothrombinase
assembled with 1nM rfVaMI. Since the ability of the rfVaFF/MI to properly interact with
fXa is compromised figure 4 also demonstrates the contribution of the light chain to the
fVa/fXa interaction and the importance of the heavy chain of fVa for the proper
interaction with fXa.
To visualize the activation pattern of prothrombin by prothrombinase assembled
with the various recombinant mutants SDS PAGE was employed. Figure 5 compares the
ability of prothrombinase assembled with the various recombinant molecules to activate
prothrombin as compared to the control reactions catalyzed with prothrombinase
assembled with plasma-derived fVa (panel B) and lipid-bound fXa in the absence of
cofactor (panel A). The reaction catalyzed by lipid-bound fXa demonstrate the inability
of timely prothrombin activation in the absence of cofactor, showing little consumption
of prothrombin after 1 hour of incubation and initial cleavage occurring at Arg271 as
evident by the formation of the prethrombin 2 intermediate. When 10nM plasma derived
fVa is added into the reaction mixture all of the prothrombin is consumed within the first
10 minutes of the reaction demonstrating the optimal rate of thrombin generation and a
reversal of the cleavage pattern with an initial activating cleavage occurring at Arg320 as
evident by the generation of fragment 1·2A. Panel C shows the reaction catalyzed by
prothrombinase assembled with 10nM rfVaWT and demonstrates a rate of thrombin
production comparable to that of the prothrombinase assembled with plasma-derived fVa.
Reactions catalyzed with prothrombinase assembled with 10nM rfVaFF, rfVaMI or
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Figure 2.5 – SDS PAGE analysis of prothrombinase assembled with
recombinant fVa mutants. To investigate the effects of the various rfVa mutants in
the activation of prothrombin, prothrombinase was assembled under the following
conditions: 0.5nM fXa, 10nM fVa species (when present), 10M DAPA, 20M
PCPS and 1.4M prothrombin. Panel A shows the activation of prothrombin by
lipid-bound fXa in the absence of fVa. Panel B shows the activation of prothrombin
by prothrombinase assembled with plasma derived fVa. Panel C-F shows the
activation of prothrombin assembled with the recombinant fVa molecules, rfVaWT,
rfVaFF, rfVaMI and rfVaFF/MI respectively. Reaction mixtures were assembled in
trizma buffered saline solutions in the presence of 5mM CaCl2 and aliquots were
removed and prepared for SDS PAGE before and 20, 40, 60, 80, 100, 120, 140, 160,
180, 200, 220, 240, 300, 360, 600, 1200, 1800 and 3600 seconds after the addition of
fXa. The prothrombin derived fragments are labeled: II, prothrombin (residues 1579); F1·2A, fragment 1·2 A chain (residues 1-320); F1·2, fragment 1·2 (residues 1271); P2, prethrombin 2 (residues 271-579); B, B chain of thrombin (residues 321579) and F1, fragment 1 (residues 1-155).
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Table 2.1

Enzyme

Prothrombinase Consumption

Fold Decrease

moles consumed/moles fXa
Lipid-Bound fXa

0.0 + 0.09

fVaWT Assembled
Prothrombinase

15.4 + 0.9

fVaFF Assembled
Prothrombinase

4.9 + 0.4

3.14

fVaMI Assembled
Prothrombinase

6.7 + 0.03

2.3

fVaFF/MI Assembled
Prothrombinase

0.92 + 0.08

16.7

Table 2.1 – Densitometry scanning of SDS PAGE in figure 5 of the rate of
prothrombin consumption. Densitometry scanning of the acrylamide gels presented in
figure 5 was performed to determine the rates of prothrombin consumption by
prothrombinase assembled in the presence of the respective rfVa mutants. Rates are
presented as moles of prothrombin consumed per mole of fXa and the fold decrease in the
observed rates as compared to the reaction performed with prothrombinase assembled
with rfVaWT is presented.
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rfVaFF/MI are shown in panels D – F respectively. All of the recombinant mutants when
assembled into a prothrombinase complex generate initial prothrombin activating
cleavage at Arg320 as evident by generation of fragment 1·2A, though production of the
meizothrombin intermediate is delayed for all of them. The prothrombinase catalyzed
reactions assembled with rfVaFF and rfVaMI took over 30 minutes to consume all of the
prothrombin present within the reaction, while prothrombinase assembled with rfVaFF/MI
was incapable of consuming all of the prothrombin present within the reaction mixture
even after an hour incubation.
Densitometry scanning of SDS PAGE presented in figure 5 was performed to
generate rates of prothrombin consumption presented in table 1. The optimal rate of
prothrombin consumption under the condition employed throughout this series of
experiments was 15.4 moles of prothrombin consumed per second per mole of fXa. The
fold decrease of prothrombin consumption for the prothrombinase assembled with rfVaFF
and rfVaMI mutants were approximately the same being 3.2 and 2.3 respectively. While
the fold decrease for the prothrombinase assembled with rfVaFF/MI was much greater
being 16.7 times slower in generating thrombin as compared to the prothrombinase
assembled with the rfVaWT.
To assay the defective association between the recombinant fVa mutants with fXa
in a more quantitative fashion the recombinant proteins were titrated against a limiting
concentration of fXa to determine the apparent Kd values for the association of the fVa
mutants with fXa. Figure 6 shows the results of this kinetic study using an activity based
assay monitored through the cleavage of the chromogenic substrate S-2338, specific for
thrombin. Prizma graphing software was used to generate the graph presented in figure 6
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Figure 2.6
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Figure 2.6 – Titration of rfVa molecules. To determine the apparent kd values for the
recombinant rfVa molecules for fXa, fVa titrations were performed. Increasing
concentrations of the respective rfVa molecules were assembled into prothrombinase
in the presence of 15pM fXa, 10M DAPA, 20M PCPS and 1.4M prothrombin.
Initial velocity of thrombin generation was assayed through the cleavage of the
chromogenic substrate S-2238 and quantified by comparison to a thrombin standard.
The empirically derived kd values are presented in table 2.
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Table 2.2

fVa Species

KdApp
nM

fVaWT

0.18 + 0.02

fVaFF

0.7 + 0.3

fVaMI

1.8 + 0.7

fVaFF/MI

10.9 + 2.4

Table 2.2 – Apparent kd values for the rfVa molecules for fXa. The empirically
derived kd values for the association of the various rfVa molecules with fXa.
Values were determined by using Prisma 2.01 Graphing software to analyze the
data presented in figure 6.
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as well as the apparent Kd values that are presented in table 2. Comparison of the
apparent Kd values for the rfVaWT and the plasma-derived fVa demonstrate similar
values for the interaction between these two molecules with fXa and is consistent with
Kd values presented throughout the literature. The rfVaFF and rfVaMI displayed impaired
association with fXa as demonstrated by the 4-fold and 10-fold increase in the apparent
Kd values respectively. When the two sets of mutations within the A2 domain of fVa are
combined within the rfVaFF/MI mutant the increase in the apparent Kd value becomes 60fold showing a greatly hampered interaction between the rfVaFF/MI mutant and fXa.
The determination of the apparent Kd values for the recombinant mutants enabled
us to study the effects of the induced mutations to the overall function of the
prothrombinase complex. The degree of saturation of fXa in the presence of a known
concentration of the respective recombinant fV molecule was determined using the
apparent Kd value. Equation 1 allows us to predict the percentage of fXa associated with
the respective recombinant fVa molecules depending on the concentration of fVa used in
the reaction thus allowing us to match the concentration of the prothrombinase complex
(17). Matching the concentration of the prothrombinase complex, fXa associated with the
respective recombinant fVa mutants, allowed us to measure the catalytic efficiencies of
the different prothrombinase molecules. Figure 7 shows the results of matching
concentrations of prothrombinase assembled with the various recombinant fVa molecules
titrated with prothrombin as a means of measuring the apparent Kcat and Km values for the
different prothrombinase molecules. The prothrombinase assembled with rfVaWT
displayed Km and Kcat values comparable to that of the prothrombinase assembled with
plasma derived fVa demonstrating that there was no functional defect with the wild type
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Figure 2.7
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Figure 2.7 – Determination of apparent Km and Kcat values. Prothrombinase
assembled with saturating concentrations of the respective rfVa molecules as
determined by the fVa titrations performed in figure 6 were performed to determine
the respective Km and Kcat values for each of the recombinant mutations. Reactions
mixtures composed of 0.5nM fXa, 20M PCPS, 10M DAPA and 5nM rfVaWT (filled
squares), 15nM rfVaWT (filled circles), 5nM plasma derived fVa (filled triangles), 5nM
rfVaFF (open diamonds), 5nM rfVaMI (opened circles), and 30nM rfVaFF/MI (filled
inverse triangles) were initiated with increasing concentrations of prothrombin. Initial
velocities were measured and quantified against a thrombin standard to determine the
thrombin (nM) produced per minute for the respective prothrombinase molecules.
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Table 2.3

VMaxApp

Km

Kcat

nMIIa/Min

M

Min-1

fVaPlasma

9.72 + 0.6

0.12 + 0.03

1944 + 120

2.7 X 10 8

fVaWT

9.85 + 0.4

0.16 + 0.02

1970 + 80

2.1 X 10 8

fVaFF

9.03 + 0.2

0.1 + 0.01

1806 + 40

3.0 X 10 8

fVaMI

10.2 + 0.24

0.14 + 0.01

2040 + 48

2.4 X 10 8

fVaFF/MI

2.03 + 0.07

0.15 + 0.02

406 + 14

4.5 X 10 7

Species

Kcat/Km
S-1 · M-1

Table 2.3 – Empirically derived kinetic values from prothrombin titrations
presented in figure 7. The apparent Vmax, Km and Kcat values as determined using
Prisma 2.01 Graphing software to analyze the prothrombin titrations presented in figure
7 are shown for all of the prothrombin titrations performed.
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protein. These values were also consistent with the kinetic values well established
throughout the literature. Both the rfVaFF and the rfVaMI demonstrated similar Kcat and
Km values when the concentration of the cofactor molecules were increased to produce
similar concentration of fXa associated with the respective mutant cofactor. However
prothrombinase assembled with saturating concentrations of the rfVaFF/MI molecule failed
to recover the catalytic efficiency displayed by the other molecules used throughout this
study. This deficiency is the result of the decreased Kcat displayed by prothrombinase
assembled with the rfVaFF/MI and can be attributed to the weakened interaction of the
rfVaFF/MI molecule with fXa. Table 3 shows the kinetic values obtained from figure 7 and
demonstrate that none of the recombinant fVa molecules, when assembled into
prothrombinase, affect the Km of the enzyme as evident by the small variance in the
apparent Km values obtained. However the effect of the Kcat of the enzyme due to the
weakened fVa/fXa interaction caused by the mutations within the proposed binding site
varied greatly, suggesting that the proper interaction of the A2 domain of fVa with fXa is
a prerequisite for optimal catalytic efficiency of prothrombinase.
The kinetic study provided within figures 6-7 and tables 1-2 enable the calculation
of the thermodynamic cycle presented in figure 8. As figure 8 demonstrates, the
interaction between the two mutated regions demonstrated an additive effect suggesting
that the two mutated regions (i.e., rfVaFF and rfVaMI) have a cooperative effect between
each other when the heavy chain of fVa associates with fXa. The overall exchange in free
energy between the two altered sites as determined by equation 4 is 1.21 kcal/mol
demonstrating that the two sites interact with each other when the associating with fXa.

46

Figure 2.8
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Figure 2.8 – Thermodynamic cycle for prothrombinase assembled with the
various rfVa molecules. The GINT is the free energy of the interaction between the
323
EY324 and 330EV331 residues and was calculated according to equation 4 as presented
in the materials and methods section.
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To assay the effects of the decreased fVa/fXa interaction on the individual
prothrombin activating cleavages independently of each other, SDS PAGE was employed
on prothrombinase catalyzed activation of the recombinant prothrombin mutants rP2-II
(R155  A, R284  A and R320  A) and rMZ-II (R155  A, R271  A and R284  A)
which are only capable of being cleaved at Arg271 and Arg320 respectively. Figure 9
shows the results from reactions using the different prothrombin mutants as substrate for
the enzymes; lipid-bound fXa (panel A), prothrombinase assembled with plasma-derived
fVa (panel B), prothrombinase assembled with rfVaWT (panel C), prothrombinase
assembled with rfVaFF (panel D), prothrombinase assembled with rfVaMI (panel E) and
prothrombinase assembled with rfVaFF/MI (panel F). Prothrombinase assembled with
rfVaWT (panel C) displayed comparable catalysis of both of the prothrombin mutants
when compared to prothrombinase assembled with plasma-derived fVa. Prothrombinase
assembled with the rfVaFF (panel D) and rfVaMI (panel E) displayed slower consumption
of both rP2-II and rMZ-II approximately 8 and 5 fold respectively as shown in table 4.
While the prothrombinase assembled with rfVaFF/MI showed the greatest deficiency when
using rP2-II or rMZ-II as substrates. Densitometry scanning of SDS PAGE presented in
figure 9 was performed and the results are presented in table 4 establishing that the fold
decrease in the ability of prothrombinase assembled with rfVaFF or rfVaMI respectively to
cleave both substrates rP2-II and rMZ-II are similar. Interestingly the reactions performed
in the presence of prothrombinase assembled with rfVaFF/MI showed a dissimilar fold
decrease in its ability to cleave rP2-II (an 8.8-fold decrease) or rMZ-II (a 17.6-fold
decrease) suggesting that the interaction of the A2 domain with fXa is more important for
the catalyzed cleavage at Arg320.
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Figure 2.9
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Figure 2.9 – Prothrombinase assembled with the various rfVa mutants were assayed
for their ability to cleave the recombinant prothrombin mutants rP2-II and rMZ-II
which are only capable of being cleaved at one of the two activating sites as described
in the experimental procedures section. Reactions mixtures were composed of by
0.5nM fXa, 10nM fVa species (when present), 10M DAPA, 20M PCPS and 1.4M
of the respective recombinant prothrombin molecules in a HEPES buffered saline
solution. In all cases lanes 1-9 shows reactions using the rMZ-II mutant as the
substrate, while lanes 10-18 are reactions which employed the rP2-II mutant as the
substrate. Panel A shows the results from a fXa catalyzed reactions, panel B shows the
results from a reactions catalyzed by prothrombinase assembled with plasma derived
fVa, panel C shows the reactions catalyzed by prothrombinase assembled with
rfVaWT, Panel D shows the reactions catalyzed by prothrombinase assembled with
rfVaFF, panel E shows the reactions catalyzed by prothrombinase assembled with
rfVaMI and panel E shows the reactions catalyzed by prothrombinase assembled with
rfVaFF/MI. For all of the reactions lanes 1-9 and 10-18 are aliquots removed from
reactions mixtures and quenched at the following time points after the addition of fXa:
0 min (before the addition of fXa), 0.5 min, 1 min, 2.5 min, 4 min, 6 min, 10 min, 20
min and 30 min. The prothrombin derived fragments are the same as explained in the
figure legend to figure 5.
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Table 2.4

Enzyme

Factor Xa alone
Prothrombinase
with wild type
Prothrombinase
with factor VaFF
Prothrombinase
with factor VaMI
Prothrombinase
with factor VaFF/MI

rMZ-II
(Cleavage
at Arg320)
Fold
(moles consumed • decrease
sec-1 • mole
factor Xa-1)
0.07 ± 0.11
--

rP2-II
(Cleavage
at Arg271)
(moles consumed
• sec-1 • mole
factor Xa-1)
0.05 ± 0.08

Fold
decrease

--

24.6 ± 2.8

--

2.72 ± 0.23

--

2.8 ± 0.2

8.8

0.33 ± 0.04

8.2

4.6 ± 0.5

5.3

0.52 ± 0.04

5.2

1.4 ± 0.1

17.6

0.31 ± 0.06

8.8

Table 2.4 – Densitometry scanning of the consumption of recombinant
prothrombin molecules. The SDS PAGE presented within figure 9 were subjected to
densitometry scanning to determine the rate of prothrombin consumption by
prothrombinase assembled in the presence of the various fVa molecules. The fold
decrease of the rate of consumption of the recombinant prothrombin molecules were
measured by comparison to the rate of prothrombin consumption by prothrombinase
assembled with rfVaWT.
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2.5 DISCUSSION
Previous studies demonstrated that activated protein C (APC) degrades fVa in a
fashion resulting in the removal of the A2 domain from fVa and a loss of the fVa/fXa
interaction (21,22). Synthetic peptides designed to study this region have shown that
N42R (a synthetic peptide designed with the corresponding sequence from residues 307348 of the heavy chain of fVa) is capable of mimicking the APC degradation of fVa loss
of function by strongly inhibiting prothrombinase activity (23). Further peptide studies
have shown that residues 323-324 and 330-331 in fVa are involved in binding fXa and
are required for the coordinated cleavage of prothrombin by fXa (11-13). All of the above
studies imply the involvement of the A2 domain of fVa in the recognition fXa. The
present study explores these residues involvement in both the assembly and function of
prothrombinase through the generation of recombinant molecules with mutations in these
residues.
The elevated Kd values for prothrombinase assembled with the rfVaFF, rfVaMI and
rfVaFF/MI molecules illustrate a decreased interaction between the respective molecules
with fXa and demonstrate the necessity of these residues for the proper interaction of fVa
with fXa. All of the recombinant molecules when assembled into prothrombinase
displayed similar Km values indicating that the induced mutations had no detrimental
effect on the ability of the different prothrombinase molecules in recognizing the
substrate prothrombin and showing the selective nature of the damaging effects of the
mutated sites. Both the rfVaFF and rfVaMI mutants were able to fully recover their
catalytic efficiency when their respective concentrations were increased to compensate
for their weakened interaction with fXa. This was not the case when the two mutated
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regions were joined together into a single construct, the catalytic efficiency of
prothrombinase assembled with rfVaFF/MI was not restored when fXa was fully saturated
with the rfVaFF/MI. The loss of multiple binding sites for fXa could have caused a
damaging in fVa’s ability to function as a cofactor molecule for fXa, one that could not
be compensated for by simply increasing the concentration of rfVaFF/MI, though the
possibility that the induced mutations altered the conformation of fV in a manner that was
detrimental to function of prothrombinase cannot be excluded as an opposing cause of the
result presented within this study.
Presently this recombinant study demonstrates that decreasing the affinity of fVa for
fXa causes a decrease in the ability of prothrombinase to efficiently generate thrombin,
suggesting that the interaction of fVa with fXa increases the catalytic capability of fXa.
This study shows that residues 323, 324, 330 and 331 of the A2 domain of fVa are
important for the association between fVa and fXa and that the loss of any of these sites
will result in a weakened interaction between fVa and fXa that can be compensated for
by increasing the concentration of the cofactor molecule, but a loss of all of these
residues result in a cofactor molecule that is incapable of interacting properly with fXa
and consequently incapable of properly functioning as a cofactor.
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CHAPTER III
A CONTROL SWITCH FOR PROTHROMBINASE
3.1 ABSTRACT
Previous studies have demonstrated that residues 695-698 of the A2 domain of the heavy
chain of fVa are involved in recognition of prothrombin by prothrombinase and that a
synthetic peptide representative of this region strongly inhibits prothrombinase by
substrate depletion. We have shown that a pentapeptide representative of this region
(DYDYQ (D5Q)) strongly inhibits thrombin generation by prothrombinase by
specifically inhibiting the initial prothrombinase catalyzed cleavage of prothrombin at
R320. In contrast, the interaction of D5Q with prothrombin accelerates the rate of initial
cleavage at R271 of prothrombin in reactions catalyzed by lipid-bound fXa, however
thrombin production is inhibited due to a slower rate of the subsequent cleavage at R320
of the prethrombin2/fragment 1·2 intermediate. Recombinant prothrombin molecules
only capable of being cleaved at one of the activation sites were used to confirm results
obtained with plasma-derived prothrombin; rMZ-II (R155  A, R271  A and R284  A)
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and rP2-II (R155  A, R284  A and R320  A). Comparison of prothrombinase
inhibition by D5Q with the hirudin derived peptides demonstrated dissimilar inhibitory
patterns. While the hirudin peptides strongly inhibited the prothrombinase catalyzed
activation of prethrombin 1 in the absence and the presence of fragment 1, D5Q
demonstrated little inhibition in these reactions. In contrast the prothrombinase catalyzed
activation of the prethrombin 2/fragment 1·2 intermediate was strongly inhibited in the
presence of D5Q, while the hirudin peptide showed little inhibition in this reaction. In
conclusion, D5Q strongly inhibits thrombin generation by both prothrombinase and lipidbound fXa in a manner independent from the hirudin peptides.
3.2 INTRODUCTION
The maintenance of blood vessel integrity is dependent on the timely generation
of thrombin in response to vascular injury. Thrombin is generated through two sequential
activating cleavages occurring at Arg271 and Arg320 catalyzed by membrane-bound
activated factor X (fXa). Though membrane-bound fXa catalyzes both of the activating
cleavages on the zymogen prothrombin, membrane-bound fXa is inefficient in this
process in the absence of activated factor V (fVa). The association of fXa with fVa on a
membrane surface in the presence of divalent metal ions results in the formation of the
prothrombinase complex (1). The formation of the prothrombinase complex results in a
reversal of the activating cleavages of prothrombin accompanied by a 300,000 fold
increase in the rate of thrombin formation (2).
Membrane-bound fXa activates prothrombin through initial activating cleavage
occurring at Arg271 resulting in the enzymatic inactive intermediate prethrombin 2
(residues 272-579) and fragment 1·2 (residues 1-271). Subsequent cleavage of
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prethrombin 2 at Arg320 produces the active enzyme thrombin. The incorporation of fVa
into the prothrombinase complex directs catalysis by fXa in a manner resulting in a
reversal of the order of the activating prothrombin cleavages (3). The prothrombinase
complex initial cleavage of prothrombin occurs at Arg320 generating the meizothrombin
intermediate (4). Meizothrombin is an enzymatic intermediate that is quickly consumed
by prothrombinase by cleavage at Arg271 to generate thrombin. Figure 1 shows the two
pathways to thrombin generation as catalyzed by membrane-bound fXa and the
prothrombinase complex. The molecular details on fVa’s involvement in prothrombinase
are not well understood.
The zymogen factor V (fV) is composed of three homologous A domains, a B
domain and two homologous C domains that are arranged in an A1-A2-B-A3-C1-C2
fashion (5). The zymogen fV is composed of 2196 amino acids and has a relative
molecular weight of 330,000. Proteolytic activation of fV occurs through three sequential
thrombin catalyzed cleavages occurring after residues Arg709, Arg1018

and Arg1545

resulting in an amino-terminally derived heavy chain composed of residues 1-709
associated through Ca2+ to the carboxyl-terminally derived light chain composed of
residues 1546-2196 (6,7). The activated cofactor, fVa, is involved in recognition of all of
the components of prothrombinase. It is well established that both the heavy and light
chains of fVa interact with fXa and that the light chain of fVa is involved in interacting
with activated membrane surfaces (8-10). It has also been demonstrated on several
occasions that the carboxyl-terminal region of the heavy chain is involved in substrate
recognition by directly interacting with prothrombin (11-14).
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The carboxyl-terminal region of the heavy chain of fVa has a highly acidic region
that shares homology with hirudin, a known anticoagulant molecule that inhibits
prothrombin activation by directly interacting with prothrombin (15). We have recently
shown that a synthetic pentapeptide from this region with the sequence DYDYQ
(representative of residues 695-699) strongly inhibits thrombin generation by
prothrombinase (16). This peptide has also been shown to directly inhibit thrombin
mediated activation of fV (17). A recent recombinant study deleted the carboxyl terminal
region of the heavy chain of fV and showed the cofactor had decreased specific activity
in clotting assays (~80%), while activity based assays suggested an increased rate of
thrombin production (~120%) (18).
3.3 EXPERIMENTAL PROCEDURES
Materials, reagents and proteins – L--phosphatidylserine (PS) and L-phosphatidylcholine (PC) were purchased from Avanti Polar Lipids (Alabaster, AL) and
prepared as previously described (19) followed by quantification by a phosphorus assay
as previously described (20). The chromogenic substrate Spectrozyme-TH, normal
reference plasma and fII deficient plasma were purchased from America Diagnostica, Inc
(Greenwich, CT). Human -thrombin, prothrombin, prethrombin 1, prethrombin 2,
fragment 1·2, fragment 1, fragment 2, and the fluorescent thrombin inhibitor
dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide

(Dapa),

were

purchased

from

Hematologic Technologies, Inc. (Essex Junction, VT). The monoclonal antibody hFV1
coupled to Sepharose, and the two monoclonal antibodies against factor V (against the
heavy and the light chains respectively, HFVHC#17 and HFVLC#9) were provided by
Dr. Kenneth G. Mann (Department of Biochemistry, University of Vermont, Burlington,
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VT). Human fXa was purchased from Enzyme Research Laboratories (South Bend, IN).
Diisopropyl fluorophosphates (DFP), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(Hepes), Trizma base, Coomassie Blue R-250, Hirudin 54-65 (sulfated hirudin, Hir54-65
(SO3-)), hirudin 54-65 (Hir54-65, non-sulfated hirudin) and factor V-deficient plasma were
purchased from Sigma. Polyethylene glycol (Mr 8000) was purchased from J. T. Baker
(Danvers MA). The chemiluminescent reagent ECL+ and heparin-Sepharose were from
Amersham Biosciences. The thromboplastin reagent (recomboplastin) used in the clotting
assays was purchased from Beckman (Fullerton, CA). The pentapeptide DYDYQ (D5Q)
and its sulfated version (D5Q1,2) were custom synthesized by New England Peptide Inc.
(Gardner, MA) and by American Peptide Company (Sunnyvale, CA). Human fV and fVa
were purified and concentrated using methodologies previously described employing the
monoclonal antibody hFV#1 coupled to sepharose and heparin-sepharose (21-23). The
recombinant prothrombin molecules, rP2-II and rMZ-II, were prepared and purified as
previously described (24,25).
Procedures for Working with Synthetic Peptides – All peptides were custom made
by New England Peptide and stored in a desiccator at -20ºC for future use. Samples
weighing between 3 – 5mg of peptides were diluted in 1ml of water and thoroughly
mixed followed by centrifugation at 14,000RPM for 5 minutes to remove any particles
not in solution. Aliquots of every peptide preparation were frozen for sequence analysis
to confirm the concentration and composition of the peptides, and all peptides solutions
were used within a week or stored at -20°C for future use. The concentration of the
peptides was calculated based on the weight (mg) of peptide divided by the volume of
water (ml) dissolved corrected for the percent peptide concentration provided by New
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England Peptide. All calculated concentrations were confirmed through amino-terminal
sequence analysis of every peptide solution.
Measuring D5Q Inhibition of Prothrombin Activation – Activity assays
measuring the inhibitory potential of D5Q were monitored through cleavage of a
chromogenic substrate specific for thrombin. Incubation of prothrombin with increasing
concentrations of D5Q or an equivalent volume of buffer was performed for 10 minutes
before addition into reaction mixtures. Since D5Q inhibition has been shown to act on the
substrate, reactions were performed in the presence and absence of fVa to assay the
effects the interaction of prothrombin with the peptide has on prothrombinase and fXa
catalyzed reactions independently. In both cases reaction mixtures contained 20M PCPS
and 10M DAPA in a HEPES buffer containing 5mM Ca2+. Results are presented as
percent control with respect to the control reactions performed in the absence of D5Q. All
reactions were performed in triplicate and the graphing program Prisma 2.01 was used for
interpreting data and generating graphs of percent inhibition against D5Q concentration.
SDS Page Analysis of D5Q Inhibition on Prothrombin Activation. – The effects
D5Q inhibition has on prothrombin activation was visualized and monitored through SDS
PAGE of both prothrombinase and fXa catalyzed reactions. Titration of prothrombinase
and fXa catalyzed reactions with increasing concentrations of D5Q demonstrated the
concentration dependence of D5Q inhibition and indicated which pathway to
prothrombin activation was used or inhibited. Measurements of prothrombin
consumption were performed through densitometry scanning using U-SCAN-IT software.
In all cases prothrombin was incubated with increasing concentrations of D5Q for 10
minutes at ambient temperature before addition into reaction mixtures containing 20M
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PCPS, 10M DAPA and 10nM fVa when present. Aliquots of the reaction mixture
before the addition of fXa were removed and placed in two fold volume of 0.2M acetic
acid for a sample before the reaction was initiated. Reactions were initiated by the
addition of fXa and additional time points were removed along the course of the reaction
and placed into 0.2M acetic acid to stop the reaction. A centrivap was used to concentrate
all samples followed by reconstituted in 0.1M Trizma buffer, 1% BME and 1% SDS at
pH 6.8. SDS PAGE was stained with coomassie blue and densitometry scanning was
performed to measure the rates of prothrombin consumption throughout both series of
titrations. Comparison of the rates obtained from inhibited reactions to control reactions
performed in the absence of D5Q were performed.
D5Q Inhibition With Respect to Individual Prothrombin Cleavages –The effects
of D5Q inhibition on the individual prothrombin activating cleavages were determined
independently of each other using the recombinant prothrombin molecules rMZ-II and
rP2-II which are only capable of being cleaved at R320 and R271 respectively. SDS PAGE
monitored both prothrombinase and fXa catalyzed reactions titrated with D5Q using
either rMZ-II or rP2-II as substrate for the reactions. This allowed us to measure the
inhibitory effect of D5Q on both prothrombin activating cleavages independently.
Incubation of the respective prothrombin mutants with D5Q was performed at ambient
temperature for 10 minutes before addition into the reaction mixtures. Aliquots of 5g
were removed from reaction mixture before and at specific time intervals after the
addition of fXa and placed in two fold volume of 0.2M acetic acid followed by
concentration in a centrivap for preparation of SDS PAGE. Stained gels were subjected to
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densitometry scanning to measure the rate of rMZ-II or rP2-II consumption and
compared to the rates of the uninhibited control reactions performed at the same time.
Plasma-Derived Prothrombin Fragments - Since the activation of prothrombin
consists of more than one activating cleavage, the physiological substrates of
prothrombinase include all of the normally occurring prothrombin derivatives. The
prothrombin fragments used throughout this series of experiments were purchased from
HTI and consist of prothrombin (residues 1-579), prethrombin 1 (residues 156-579),
prethrombin 2 (residues 272-579), fragment 1·2 (residues 1-271), fragment 1 (residues 1155) and fragment 2 (residues 156-271). All proteins were dialyzed in trizma buffered
saline solution composed of 20mM trizma at pH 7.40 containing 5mM CaCl2. Their
concentrations were determined using the extinction coefficients (1%280nm) and molecular
weights as follows; prothrombin 13.8 and 72,000, prethrombin 1 17.8 and 50,500,
prethrombin 2 17.3 and 37,000, fragment 1·2 11.2 and 34,500 and thrombin 18.3 and
36,700. Protein aliquots were frozen after dialysis for future use. Reactions using the
substrate prethrombin 1 were performed in the presence and the absence of fragment 1
and reactions using the substrate prethrombin 2 were performed in the presence and
absence of fragment 1, fragment 2 and fragment 1·2. The substrate concentration for all
reactions was at least twice that of their reported Km to ensure maximum velocity of the
uninhibited enzyme and specific reaction conditions are given in the figure legends.
Activity Assays for Determining Thrombin Production – Measurements of the rate
of activation of prothrombin and prothrombin derived fragments were performed in a
discontinuous assay monitored through cleavage of a chromogenic substrate specific for
thrombin (Spectrozyme TH, America Diagnostica). Reactions mixtures were prepared in
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a HEPES buffered saline (20mM HEPES) solution containing 5mM CaCl 2 and initiated
by the addition of fXa. Several time points from the first two minutes of the reaction were
removed and immediately quenched in a HEPES buffered saline solution containing
EDTA to stop the reaction. All reactions were compared to a thrombin standard for
quantitative purposes. Initial velocities were determined using Prism graphing software to
generate graphs of OD vs. time (seconds) followed by comparison of the slopes of the
reactions to a thrombin standard for quantification of reactions. Results using peptides
were always compared to reactions performed without peptide and percent inhibition was
determined by comparison of inhibited reactions to the control reactions.
SDS PAGE of Reactions – In all cases the substrate used in any reaction was
incubated in the presence of D5Q for ten minutes at ambient temperature before addition
into reaction mixtures. Reactions catalyzed by prothrombinase or fXa alone were initiated
by the addition of fXa. Aliquots of 4-6g of protein from the reaction mixture were
removed at various time points determined empirically dependent on the substrate used
(i.e. prothrombin, prethrombin 1 or prethrombin 2) and placed in a two-fold volume of
0.2 M acetic acid to stop the reaction. Samples were then concentrated using a centrivap
attached to a cold trap and suspended in a loading buffer containing 1% SDS and 1%
BME followed by preparation for SDS PAGE. Control reactions performed in the
absence of peptides were performed simultaneously with reactions performed in the
presence of peptide as a means of ensuring any differences in reaction rates or pathways
were due to the presence of the peptides being used. Differences in cleavage patterns
were determined according to molecular weights of products and confirmed through
amino terminal sequencing. Differences in the rates of cleavage were determined by
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densitometry scanning of SDS-PAGE followed by comparison to control reactions
performed in the absence of peptide.
3.4 RESULTS
Previous studies demonstrated that the pentapeptide D5Q was a competitive
inhibitor of prothrombinase with respect to prothrombin and that inhibition occurred by
substrate depletion. The current study was performed to ascertain the effect D5Q has on
the pathway to thrombin generation by prothrombinase. Figure 2 shows the titration of a
prothrombinase catalyzed reaction with D5Q. The titration demonstrates that inhibition is
concentration dependent and shows 50% inhibition occurs at 7.5M D5Q under the
conditions employed. As the concentration of D5Q was increased complete inhibition
never occurred though approached 100% inhibition at 15M D5Q.
To directly assay the effect of the peptide on the pathway to thrombin generation
in a prothrombinase catalyzed reaction SDS PAGE was performed. This allowed the
determination of the intermediates involved. The results presented in figure 3 show the
effect D5Q has on the pathway to prothrombin activation. Panel A shows a control
reaction performed in the absence of peptide and demonstrates the normal pathway to
thrombin production by prothrombinase. Prothrombin is rapidly consumed with initial
activating cleavage occurring at Arg320 producing meizothrombin, as evident by the
appearance of fragment 1·2A. The subsequent cleavage at Arg271 quickly consumes the
transient meizothrombin intermediate and generates thrombin and fragment 1·2. All of
the prothrombin present within the reaction mixture is consumed within ten minutes
resulting in complete conversion of the prothrombin to thrombin. Panel B shows a
prothrombinase catalyzed activation of prothrombin in the presence of a saturating
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Figure 3.1

Arg155 Arg284

NH2-

-COOH




S

S

Prothrombin

Pathway I

Factor Xa
Membran
e

Arg271

Pathway II

Factor
Xa/Va
Membrane

Arg320
S

S S

Fragment 1•2 Prethrombin 2




S

Meizothrombin

Achain

B chain
S

Fragment 1•2

S

Thrombin

Figure 3.1 – The activation of prothrombin. Pathway 1 - Membrane-bound fXa
catalyzes initial cleavage at Arg271 producing the inactive intermediate prethrombin 2
and fragment 1·2. Prethrombin 2 is then sequentially cleaved at Arg320 to produce
thrombin and fragment 1·2. Pathway 2 – In the presence of fully assembled
prothrombinase complex the rate of thrombin generation is greatly enhanced and the
order of the activating cleavages on prothrombin are reversed. Prothrombinase initially
cleaves prothrombin at Arg320 generating the active enzymatic intermediate,
meizothrombin. Meizothrombin is then cleaved at Arg271 to produce thrombin and
fragment 1·2.
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Figure 3.2
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Figure 3.2 – DYDYQ titration of prothrombinase catalyzed activation of
prothrombin. Reaction mixtures composed of 5nM fVa, 0.5nM fXa, 50M DAPA
and 10M PCPS assembled in a HEPES buffered saline solution containing 5mM
CaCl2 were started by the addition 1.4M prothrombin that was incubated with
increasing concentration of DYDYQ for ten minutes. All reactions were performed in
triplicate and compared to control reactions that were performed in the absence of
DYDYQ. Error bars are representative of standard deviance and Prisma Graphing
software was used in generating the graph.
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Figure 3.3
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Figure 3.3 – SDS PAGE analysis of prothrombin activation. Reactions performed
in the absence and the presence of DYDYQ were subjected to SDS PAGE analysis to
determine the effect DYDYQ had on the pathway to thrombin generation. Panel A
shows a prothrombinase catalyzed reaction demonstrating the optimal rate of the
reaction with initial cleavage occurring at Arg320 as evident by the presence of F1·2A.
Panel B shows a prothrombinase catalyzed reaction performed in the presence of
20M DYDYQ and demonstrates initial cleavage occurring at Arg271 as evident by the
presence of prethrombin 2. Aliquots from both reaction mixtures were removed at 0,
20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 300, 360, 600, 1200, 1800 and
3600 seconds after the addition of fXa. The prothrombin derived fragments are
labeled: II, prothrombin (residues 1-579); F1·2A, fragment 1·2 A chain (residues 1320); F1·2, fragment 1·2 (residues 1-271); P2, prethrombin 2 (residues 271-579); B, B
chain of thrombin (residues 320-579).
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concentration of D5Q (20M). In the presence of 20M D5Q prothrombin consumption
by prothrombinase is greatly delayed with the initial activating cleavage occurring at
Arg271 as evident by the occurrence of prethrombin 2 and fragment 1·2. The subsequent
cleavage occurring at Arg320 produces thrombin at a greatly delayed rate. Prothrombin
was still present within the reaction mixture after an hour of incubation.
To determine the concentration dependence of the peptide on the switch in
pathways and the concentration at which meizothrombin formation is completely
inhibited a titration of D5Q on a prothrombinase catalyzed reaction was monitored
through SDS PAGE. Figure 4 shows the effects of increasing concentrations of D5Q on
prothrombinase activation of prothrombin. Panels A – D demonstrate the disappearance
of fragment 1·2A, representative of meizothrombin, corresponding to an increased
production of prethrombin 2 as seen in panels C – F. As the concentration of D5Q is
increased from 2M to 4.2M the preferred pathway to thrombin formation by
prothrombinase switches from the meizothrombin intermediate to the prethrombin 2
intermediate, because the initial activating cleavage of prothrombin by prothrombinase
switches from Arg320 to Arg271 and consequently the rate at which prothrombin is
consumed is greatly inhibited. Densitometry scanning of SDS PAGE presented in figure
4 show the rate decrease of prothrombin consumption in the presence of varied
concentrations of D5Q. A 41-fold decrease in the rate of prothrombin consumption is
observed as the concentration of the peptide is raised to 20M.
To assay the peptide’s effect of the peptide on both prothrombin activating
cleavages independently of each other, two recombinant prothrombin mutants were
employed which were only capable of one activating cleavage. The prothrombin mutants
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Figure 3.4
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Figure 3.4 – SDS PAGE analysis of DYDYQ titration of prothrombinase
catalyzed reaction. Plasma derived prothrombin was incubated with increasing
concentrations of DYDYQ as indicated in the figure. The time points and the
prothrombin derived fragments are the same as indicated in figure legend 3. The
concentrations of DYDYQ used throughout this experiment were: Panel A,
prothrombinase in the presence of 0M DYDYQ; panel B, prothrombinase in the
presence of 0.2M DYDYQ; panel C, prothrombinase in the presence of 2M
DYDYQ; panel D, prothrombinase in the presence of 4.2M DYDYQ; panel E,
prothrombinase in the presence of 8.5M DYDYQ; panel F, prothrombinase in the
presence of 16.5M DYDYQ.
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Table 3.1
Peptide Concentration
M
0
0.2
4.2
8
8.5
16.5
20

Plasma-derived
Prothrombin
moles consumed · s1
· mole fXa-1
8.2 + 0.6
5.4 + 0.6
3.2 + 0.4
0.87 + 0.3
0.5 + 0.2
0.4 + 0.2
0.2 + 0.2

Fold Decrease

1.5
2.6
9.4
16.4
20.5
41

Table 3.1 – Scanning densitometry. The rates of prothrombin consumption in the
presence of increased DYDYQ concentrations were generated through densitometry of
the gels presented in figures 3 and 4. The fold decrease in the rate of prothrombin
consumption was generated as a ratio of the prothrombinase catalyzed reaction
performed in the absence of DYDYQ to the prothrombinase catalyzed reaction in the
presence of DYDYQ.
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rMZ-II (R155  A, R271  A and R284  A) and rP2-II (R155  A, R284  A and R320 
A) were used in prothrombinase catalyzed reactions performed in the presence and
absence of D5Q to assay the peptide’s effect on the individual activating cleavages
independently of each other. Figure 5 presents SDS PAGE analysis of prothrombinase
catalyzed reactions performed on rMZ-II (panel A) and rP2-II (panel B). Panel A shows
the reaction performed in the absence of D5Q in lanes 1 – 9 and the reaction performed in
the presence of D5Q, lanes 10 – 18, demonstrating the inhibition of the initial cleavage at
Arg320. Panel B shows the prothrombinase catalyzed activation of rP2-II in the absence
(lanes 1 – 9) and the presence of D5Q (lanes 10 – 18) and demonstrates that D5Q has
little effect on the activating cleavage of prothrombin at Arg271. Densitometry scanning of
SDS PAGE presented in figure 5 and SDS PAGE not shown are presented in table 2 and
demonstrate the selective inhibition of D5Q on the activating cleavage at Arg320, when
the reaction is catalyzed by prothrombinase. Although at high D5Q concentrations
inhibition of initial activating cleavage at Arg271 is observed.
To assay the effect of the interaction of D5Q with prothrombin has on the fXa
catalyzed activation of prothrombin activity assays monitored through the cleavage of a
chromogenic substrate were performed on a D5Q titration. Figure 6 shows the titration of
D5Q on the activity of a fXa catalyzed activation of prothrombin 50% inhibition occurred
at a 12M D5Q concentration. However concentrations of D5Q as high as 48M were
incapable of completely inhibiting thrombin formation by fXa. SDS PAGE analysis of
the lipid-bound fXa catalyzed activation of prothrombin demonstrated a greatly
accelerated rate of prothrombin consumption, but showed a delayed generation of
thrombin. Figure 7 demonstrates the rapid consumption of prothrombin with the
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Figure 3.5
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Figure 3.5 – Analysis of prothrombinase catalyzed activation of recombinant
prothrombin molecules in the absence and presence of DYDYQ. Reactions were
performed using the recombinant prothrombin molecules rMZ-II and rP2-II which are
only capable of being cleaved at Arg320 and Arg271 respectively. Lanes 1-9 and 10-18
are aliquots that were removed before the addition of fXa and 1, 4, 6, 10, 20, 30, 45
and 60 minutes after the addition of fXa. The table was generated through
densitometry scanning and gives the rate of prothrombin consumption in the absence
and the presence of DYDYQ for both of the respective recombinant prothrombin
molecules.
* The rates that are presented are moles consumed · s-1· mole fXa-1
** NS, not significant consumption.
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Figure 3.6

100

80

60

40

20

0

0

1.2

2.4

6

12

24

48

M DYDYQ

Figure 3.6 – DYDYQ titration against membrane-bound fXa catalyzed activation
of prothrombin. Prothrombin (1.4M) was incubated with increased concentrations
of DYDYQ for ten minutes before addition into a reaction mixture containing fXa.
The initial velocity of the reactions were measured and compared to reactions
performed in the absence of DYDYQ. All measurements were performed in triplicate
using different protein and peptide preparations and error bars are representative of
standard deviation.
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Figure 3.7
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Figure 3.7 – SDS PAGE analysis of membrane-bound fXa activation of
prothrombin in the absence and the presence of DYDYQ. Plasma-derived
prothrombin was incubated with DYDYQ or an equivalent volume of buffer for ten
minutes before addition into a reaction mixture containing 2.5nM fXa. Panel A is the
reaction that was performed in the absence of DYDYQ and panel B is the reaction that
was performed in the presence of 24M DYDYQ. Lanes 1-19 are aliquots that were
removed before the initiation of the reaction and 0.5, 1, 3, 5, 7, 10, 12, 15, 20, 30, 45,
60, 75, 90, 105, 120, 150 and 180 minutes after the reaction was started. The
prothrombin fragments are the same as described in figure 3 with the additional
fragments being: P1, prethrombin 1 (residues 156 – 579) and F1, fragment 1 (residues
1 – 155).
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accumulation of the prethrombin 2 intermediate, evident of initial activating cleavage
occurring at Arg271. However the production of thrombin is greatly delayed as evident by
the delayed appearance of the B-chain of thrombin, meaning the subsequent cleavage of
the prethrombin 2/fragment 1·2 at Arg320 is strongly inhibited.
To evaluate the effects D5Q has on the individual activating cleavages
independently in a fXa catalyzed reaction the recombinant prothrombin mutants rMZ-II
and rP2-II were once again employed. Figure 8 shows SDS PAGE analysis of the fXa
catalyzed activation of the recombinant prothrombin molecules in the absence and the
presence of D5Q. Panel A shows the cleavage of the rMZ-II prothrombin mutant by
lipid-bound fXa and demonstrates that the presence of D5Q (lanes 10-18) has little effect
on the activating cleavage at Arg320 when compared to the control reaction performed in
the absence of peptide (lanes 1-9). Panel B shows the consumption of the rP2-II
prothrombin mutant by lipid-bound fXa (lanes 1-9) and demonstrates a greatly
accelerated rate of the cleavage at Arg271 in the presence of 20M D5Q (lanes 10-18).
Densitometry scanning of the SDS PAGE presented in figures 7 and 8 and additional
SDS PAGE of reactions performed in the presence of different D5Q concentrations not
shown are presented in table 3. A D5Q concentration of 48M accelerated the rate of
plasma derived prothrombin consumption by lipid-bound fXa by 50-fold, while a lower
concentration of D5Q (24M) accelerated the rate of rP2-II consumption by lipid-bound
fXa 70-fold. Table 3 also demonstrates that D5Q has little effect on the rate of proteolysis
at Arg320 as evident by the similar rate of rMZ-II consumption by lipid-bound fXa in the
absence or presence of D5Q.
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Figure 3.8
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Figure 3.8 – Analysis of the activation of the recombinant prothrombin molecules
by membrane-bound fXa. Membrane-bound fXa was used in SDS PAGE monitored
reactions with the two prothrombin mutants rMZ-II and rP2-II as substrates used in the
reactions performed in the presence and absence of DYDYQ. Lanes 1-9 and 10-18 are
aliquots of the reaction mixture that were pulled out before initiation of the reaction
and 5, 15, 30, 60, 90, 120, 150 and 180 minutes after the addition of fXa into the
reaction mixture. The prothrombin derived fragments are the same as explained in
figure legend 3.
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Table 3.2
Peptide
Concentration
(M)
0
12
20
24
48

Plasma-derived
Prothrombin
0.06 + 0.03*
2 + 0.3

rMZ-II

rP2-II

0.08 + 0.022

0.014 + 0.005
0.3 + 0.09
0.5 + 0.09
1 + 0.4

0.06 + 0.03
3.1 + 0.2
3 + 0.7

Table 3.2 – Rates of prothrombin consumption by membrane-bound fXa.
Densitometry scanning of the SDS PAGE shown in figures 7 and 8 were performed to
measure the rates of consumption of prothrombin and recombinant prothrombin
mutants rMZ-II and rP2-II in reactions performed in the absence and presence of
increasing concentrations of DYDYQ.
* Rates of prothrombin consumption are measured as moles consumed · s-1 · mole
fXa-1.
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Since the carboxyl-terminal portion of the heavy chain of fVa shares homology
with the hirudin derived anti-coagulant peptide molecules, we next investigated the
similarity of inhibition between D5Q and the hirudin derived peptides. It has been
previously determined that the hirudin peptides’ interaction with thrombin enhances the
ability of thrombin to cleave thrombin specific chromogenic substrates. To investigate the
possibility that the interaction of D5Q has a similar effect on thrombin’s ability to cleave
chromogenic substrates, D5Q and the hirudin peptides were incubated in the presence of
thrombin before the addition of the chromogenic substrate S-2338. Figure 9 show that the
interaction of the sulfated and non-sulfated versions of the hirudin peptides increases the
rate of cleavage of S-2338, while the interaction of D5Q with thrombin does not enhance
the observed rate. This indicates that the hirudin peptides ability to inhibit thrombin
formation in activity assays monitored through cleavage of a chromogenic substrate are
misleading, since a dual effect is observed.
To assay the ability of the hirudin peptides on the pathway to thrombin formation
SDS PAGE of prothrombinase catalyzed activation of prothrombin were performed.
Figure 10 shows the results generated when prothrombin was incubated in the absence
and presence of 100M of the sulfated and non-sulfated versions of the hirudin peptides
(panels B and C). Panel A shows the uninhibited reaction and demonstrates the optimal
rate of thrombin generation by a prothrombinase catalyzed reaction. Panel B shows the
reaction under the same conditions, but in the presence of 100M hir54-65(SO3-) and
demonstrates approximately 50% inhibition, while panel D shows the same reaction as
monitored through the cleavage of a chromogenic substrate and implies an increased rate
of thrombin generation due to the increased activity of thrombin to cleave S-2238 in the
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Figure 3.9
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Figure 3.9 – Direct effect of peptides on thrombin’s cleavage of Spectrozyme TH.
Thrombin (50nM) was incubated in the presence of DYDYQ, Hir54-65(SO3-), and
Hir54-65 for ten minutes before addition of the chromogenic substrate, Spectrozyme
TH. After five minutes incubation the optical density of the samples were read at
405nm. All samples were performed in triplicate and error bars are representative of
standard deviation.
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Figure 3.10
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Figure 3.10 – SDS PAGE analysis of Hir54-65(SO3-) and Hir54-65 inhibition of
prothrombinase catalyzed activation of prothrombin. Panel A is a control reaction
performed in the absence of peptide. Panel B is a reaction performed in the presence
100M hir54-65(SO3-). Panel C is a reaction that was performed in the presence of
100M Hir54-65. Lanes 1-19 are representative of aliquots removed from the respective
reaction mixtures before the addition of fXa and 20, 40, 60, 80, 100, 120, 140, 160,
180, 200, 220, 240, 300, 360, 600, 1200, 1800 and 3600 seconds after the addition of
fXa. Panel D is a measurement of the initial rates of the reactions shown in panels A-C
that was measured through the cleavage of a chromogenic substrate specific for
thrombin and compared to a thrombin standard for quantification. Error bars are
representative of standard deviation and graph was generated using Prisma Graphing
software.
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Table 3.3

Prothrombinase
Control (no
peptide)
Hir54-65(SO3-)
Hir54-65
DYDYQ

Prothrombin
Consumption
(moles
consumed · s1 · mole fXa-1)
26.1 + 1.2
12.6 + 0.6
1.5 + 1
0.07 + 0.2

Prothrombin
Thrombin
Thrombin
Consumption Formation (nMIIa Activity
(Percent of
Formed · min(Percent
Control)
1 · nMfXa-1)
Control)
100
48.3
5.8
0.3

1770.2 + 227
2549.3 + 331
135.3 + 80
60.3 + 26

100
144
7.6
3.4

Table 3.3 – Comparison of densitometry scanning and activity based assays. SDS
PAGE from figure 10 were subjected to densitometry scanning to determine the rate of
prothrombin consumption. The rate of thrombin generation was determined through
activity based assays monitoring thrombin generation through cleavage of a
chromogenic substrate specific for thrombin. Comparison of the two methods of
determining thrombin generation demonstrates the misleading nature of monitoring
inhibition by the hirudin peptides using a chromogenic substrate specific for thrombin.
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presence of 100M hir54-65(SO3-). Panel C shows the reaction performed in the presence
of 100M Hir54-65 and demonstrates a greatly inhibited generation of thrombin, however
initial cleavage still occurs at Arg320 as evident by the generation of fragment 1·2A. Panel
D shows the rate of thrombin generation in the absence and presence of the hirudin
peptides and D5Q as determined by an activity assay monitored through the cleavage of
the chromogenic substrate S-2338, demonstrating the discrepancy of the inhibitory
potential of the hirudin peptides when monitored in this fashion. Densitometry scanning
of the SDS PAGE presented in figure 10 was performed to generate the rates of
prothrombin consumption presented in table 3, establishing the discrepancy between the
two ways of monitoring the inhibitory potential of the respective peptides.
Since the inhibition of the hirudin peptides on the generation of thrombin by
prothrombinase has previously been shown to be optimal in the absence of a membrane
surface, D5Q was next titrated against a fXa/fVa complex generated in the absence of
PCPS. Figure 11 shows a similar inhibition response to D5Q concentration as compared
to a titration of D5Q in the presence of a fully assembled prothrombinase complex
assembled on a PCPS surface. This demonstrates a contrast between the inhibition of
D5Q when compared to the hirudin peptides because the presence of a membrane surface
has little influence on the inhibitory potential of D5Q on the fXa/fVa complex.
As a means of monitoring the effect that Hir54-65(SO3-) and D5Q has on the
pathway to thrombin generation, reactions performed in the absence and presence of the
respective peptides and monitored through SDS PAGE. Figure 12 consists of time
courses of prothrombin activating reactions performed in the absence of a lipid bilayer
catalyzed by fXa (panel A), a fXa/fVa complex (panel B), a fXa/fVa complex in the
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Figure 3.11
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Figure 3.11 – DYDYQ titration of a fVa/fXa complex in the absence of PCPS. To
assay the dependency of a membrane surface on the inhibitory potential of DYDYQ a
complex of fVa/fXa was titrated with an increasing concentration of DYDYQ.
Prothrombin (500nM) was incubated in the presence of increasing concentrations of
DYDYQ for ten minutes before addition into a reaction mixture containing 10nM fXa,
5nM fVa and 3M DAPA. Initial rates of thrombin generation were measured and
reactions performed in the presence of DYDYQ were compared to reactions
performed in the absence of peptide as a means of determining the percent inhibition
due to the concentration of DYDYQ present. All reactions were performed in triplicate
and error bars are representative of standard deviation.
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Figure 3.12
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Figure 3.12 – SDS PAGE analysis of fVa/fXa complex in the presence of DYDYQ
and Hir54-65(SO3-). To monitor the effect of the peptides on the pathway to
prothrombin activation in the absence of PCPS SDS PAGE was used to monitor
reactions. Panel A is a control reaction catalyzed by fXa, in the absence of fVa. Panel
B is a control reaction performed in the presence of a fXa/fVa complex. Panel C is a
reaction catalyzed by a fXa/fVa complex performed in the presence of DYDYQ. Panel
D is a reaction catalyzed by a fXa/fVa complex performed in the presence Hir5465
(SO3-). Lanes 1-19 are aliquots that were removed from the reaction before the
addition of fXa and 0.5, 1, 3, 5, 7, 10, 12, 15, 20, 30, 45, 60, 75, 90, 105, 120, 150 and
180 minutes after the addition of fXa. The prothrombin derived fragments are the
same as identified in figure 3.
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presence of 92M D5Q (panel C) and a fXa/fVa complex in the presence of 100M
Hir54-65(SO3-). Panel A shows the ability of fXa to activate prothrombin in the absence of
PCPS, thrombin is slowly generated through initial cleavage occurring at Arg271 as
evident by the generation of the prethrombin 2 intermediate. Panel B shows a greatly
accelerated generation of thrombin due to the addition of fVa into the reaction mixture,
however in the absence of the PCPS surface the initial activating prothrombin cleavage
occurs at Arg271. The addition of Hir54-65(SO3-) (panel C) and D5Q (panel D) slows the
generation of thrombin by the fXa/fVa complex at a rate similar to that observed by the
fXa catalyzed reaction (panel A).
Prethrombin 1 is a naturally occurring derivative of prothrombin that is generated
through proteolysis at Arg155 by thrombin or fXa and results in the generation of fragment
1 (prothrombin residues 1 – 155) and prethrombin 1 (prothrombin residues 156 – 579).
Activity assays measuring thrombin generation by prothrombinase in the absence and
presence of Hir54-65(SO3-) and D5Q were performed using prethrombin 1 in the absence
and presence of fragment 1. Figure 13 shows the percent activity of these reactions and
demonstrates the inability of D5Q to inhibit prothrombinase catalyzed activation of
prethrombin 1, while Hir54-65(SO3-) inhibited prethrombin 1 activation both in the absence
and presence of fragment 1. The dissimilar inhibition of reactions performed with
prethrombin 1 as a substrate, again suggest dissimilar interaction of the two peptides with
prothrombin.
To monitor the pathways to thrombin production from the prethrombin 1 substrate
in the absence and presence of fragment one and the effects of Hir54-65(SO3-) and the D5Q
peptides SDS PAGE was performed. Figure 14 show reactions performed using
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Figure 3.13
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Figure 3.13 – Activity assays measuring prothrombinase catalyzed activation of
prethrombin 1 in the absence and presence of fragment 1. The prothrombinase
catalyzed activation of prethrombin 1 was monitored through the chromogenic
substrate specific for thrombin, Spectrozyme TH. Reactions performed in the presence
of the DYDYQ and Hir54-65(SO3-) were compared to control reactions performed in the
absence of these peptides to determine the percent inhibition. Panel A shows the
prothrombinase catalyzed activation of prethrombin 1 in the absence and the presence
of DYDYQ and Hir54-65(SO3-). Panel B shows the prothrombinase catalyzed activation
of prethrombin 1/fragment 1 in the absence and the presence of DYDYQ and Hir5465
(SO3-). All reactions were performed in triplicate and error bars are representative of
standard deviation.
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Figure 3.14
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Figure 3.14 – SDS PAGE analysis of prothrombinase catalyzed activation of
prethrombin 1. Panels A and B are control reactions monitoring the activation of
prethrombin 1 catalyzed by membrane-bound fXa (10nM) in the absence (panel A)
and presence (panel B) of fragment 1. Panels C and D are prothrombinase (1nM fXa
and 15nM fVa) catalyzed activation of prethrombin 1 in the absence (panel C) and
presence (panel D) of fragment 1. Panels E and F are the same conditions as panels C
and D, but in the presence of 92M DYDYQ. Panels G and H are the same conditions
as panels C and D, but in the presence of 100M Hir54-65(SO3-). Lanes 1-19 are
aliquots from the various reaction mixtures that were removed before the addition of
fXa and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 30, 45, 60, 90 and 120 minutes after the
addition of fXa. The prothrombin derived fragments are the same as identified in
figures 3 and 7 with F2-A being fragment 2 covalently attached to the A chain of
thrombin (residues 156 – 320).
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prethrombin as a substrate in the absence and the presence of fragment 1. Panels A and B
are control reactions catalyzed by fXa and demonstrate the insufficient generation of
thrombin by lipid-bound fXa in the absence of fVa. Panels C and D are prothrombinase
catalyzed reactions and show that in the absence of fragment 1 (panel C) both
prethrombin 1 activating cleavages occur at similar rates. When fragment 1 is added into
the reaction mixture (panel D) the initial cleavage occurs at Arg320, as evident by the
occurrence of fragment 2A, with the sequential cleavage at Arg271 occurring at an
accelerated rate. Though the consumption of prethrombin 1 by prothrombinase is slower
in the presence of fragment 1, the generation of thrombin is faster when fragment 1 is
present, because the subsequent cleavage is greatly accelerated. Panels E and F are
reactions performed in the presence of 92M D5Q and demonstrate that D5Q does not
inhibit prothrombinase catalyzed activation of prethrombin 1 in the absence (panel E) or
the presence of fragment 1 (Panel F). Hir54-65(SO3-) inhibited both the prothrombinase
catalyzed activation of prethrombin 1 in the absence (panel G) and presence of fragment
1 (panel H) as indicated by the activity assay presented in figure 13 and the SDS PAGE
presented in figure 14.
Densitometry scanning of the SDS PAGE presented in figure 14 was performed to
determine the relative rates of prethrombin 1 consumption in the absence and presence of
fragment 1 (Table 4) as well as the relative rate of generation of the B-chain of thrombin
(figure 15). Table 4 shows that the rate of prethrombin 1 consumption by prothrombinase
is 16 ± 2.9 moles consumed · s-1 · mole fXa-1, while the rate of consumption of
prethrombin 1 in the presence of fragment 1 is slower, being 11.1 ± 2.5 moles
consumed · s-1 · mole fXa-1. However, when comparing the generation of the B-chain of
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Table 3.4
Enzyme/Inhibitor

fXa alone (Control)
Prothrombinase (control)
Prothrombinase + DYDYQ
Prothrombinase + Hir54-65(SO3-)

Prethrombin 1
(moles consumed · s1 · mole fXa-1)
0.8 + 0.6
16 + 2.9
17.8 + 2.6
5.2 + 3.5

Prethrombin 1 +
Fragment 1
(moles consumed · s1 · mole fXa-1)
0.5 + 0.4
11.1 + 2.5
11.4 + 0.55
NS*

Table 3.4 – Densitometry scanning of SDS PAGE measuring the consumption of
prethrombin 1. Densitometry scanning was performed on the SDS PAGE shown in
figure 14 and the rate of prethrombin 1 consumption determined.
*NS, not significant consumption. The concentration of prethrombin 1 varied from
15M at time 0 to ~12M following 2 hr incubation with prothrombinase in the
presence of Hir54-65(SO3-).
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Figure 3.15
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Figure 3.15 – Generation of the B chain of thrombin in the absence and presence
of fragment 1. Densitometry scanning of the prothrombinase catalyzed controls
presented in figure 14 was performed to measure the generation of the B chain of
thrombin. The results are presented as density of B-chain band (arbitrary units * 103)
verses time (minute) for the prothrombinase catalyzed activation of prethrombin 1 in
the absence and the presence of fragment 1.
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thrombin as shown in figure 15, it is demonstrated that prethrombin 1 is activated
approximately 3-fold faster in the presence of fragment 1, with reversal of the initial
cleavage occurring at Arg320 as evident by the generation of fragment 2A.
We next looked at the activation of prethrombin 2 (prothrombin residues 271 –
579) in the absence and presence of fragment 1·2 (prothrombin residues 1 – 270) and
fragments derived from fragment 1·2 and the inhibitory potential of the peptides Hir5465

(SO3-) and D5Q on this substrate. Results from activity assays employing prethrombin 2

(panel A), prethrombin 2 in the presence of fragment 1·2 (panel B), prethrombin 2 in the
presence of fragment 1 (panel C), prethrombin 2 in the presence of fragment 2 (panel D),
and prethrombin 2 in the presence of both fragment 1 and fragment 2 (panel E) as
substrates in a prothrombinase catalyzed reactions are presented in figure 16. Once again
we observed a dissimilar inhibition pattern between the Hir54-65(SO3-) and D5Q peptides.
D5Q only inhibited the prothrombinase catalyzed reactions employing prethrombin 2 in
the presence of fragment 1·2, Fragment 1 or fragment 1 in addition to fragment 2 (panels
B, C and D respectively) as substrates demonstrating the necessity of the presence of
fragment 1 for D5Q inhibition in the activation of prethrombin 2. While Hir54-65(SO3-)
displayed inhibition in reactions using the substrates prethrombin 2, prethrombin 2 in the
presence of fragment 1, prethrombin 2 in the presence of fragment 2 and prethrombin 2 in
the presence of both fragment 1 and fragment 2 (panels A, C, D and E respectively).
SDS PAGE was employed to visualize the prothrombinase catalyzed activation of
prethrombin 2 in the presence of fragment 1·2 and prethrombin 2 in the presence of both
fragment 1 and fragment 2 separately. Figure 17 shows these reactions performed in the
absence and in the presence of both the Hir54-65(SO3-) and D5Q peptides. Panels A-C
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Figure 3.16
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Figure 3.16 – Prethrombin 2 activity assays. Panel A shows the activity of a
prothrombinase catalyzed activation of prethrombin 2 in the absence and presence of
DYDYQ and Hir54-65(SO3-). Panel B shows the activity of a prothrombinase catalyzed
activation of prethrombin 2/fragment 1·2 in the absence and the presence of DYDYQ
and Hir54-65(SO3-). Panel C shows the activity of a prothrombinase catalyzed activation
of prethrombin 2/fragment 1/fragment 2 in the absence and the presence of Hir5465
(SO3-). Panel D shows the activity of a prothrombinase catalyzed activation of
prethrombin 2/fragment 1 in the absence and presence of DYDYQ and Hir54-65(SO3-).
Panel E shows the activity of a prothrombinase catalyzed activation of prethrombin
2/fragment 2 in the absence and presence of DYDYQ and Hir54-65(SO3-). All reactions
were performed in triplicate and error bars are representative of standard deviation.
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Figure 3.17
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Figure 3.17 – SDS PAGE analysis of prethrombin 2 activation in the presence of
fragment 1·2. Fragment 1·2 was used before and after cleavage by fXa (to produce
fragment 1 and fragment 2 non-covalently attached) in reactions monitoring the
prothrombinase catalyzed activation of prethrombin 2 in the presence and absence of
the respective peptides DYDYQ and Hir54-65(SO3-). Panels A-C and D-F are
prothrombinase catalyzed activations of prethrombin 2 in the presence of fragment 1·2
and in the presence of fragment 1 and fragment 2 respectively. Panels B and E are
reactions performed in the presence of 76M DYDYQ and panels C and F are
performed in the presence of 100M Hir54-65(SO3-). Panels A-C had aliquots removed
from the reaction mixture before addition of fXa and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
12, 15, 20, 30, 45, 60 and 90 minutes after the addition of fXa. Panels D-F had
aliquots removed from the reaction mixture before addition of fXa, fragment 1 and
fragment 2 and 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 300, 360, 600,
1200, 1800 and 3600 seconds after the addition of the fXa, fragment 1 and fragment 2
mixture. The prothrombin derived fragments are the same as identified in figure 3 and
7 with F2 being fragment 2 (residues 156-270).
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show the results of the reaction using prethrombin 2 in the presence of fragment 1·2 as
the substrate. Panel A shows the control reaction performed in the absence of any
inhibitors and demonstrates the optimal rate of prethrombin 2 activation when fragment
1·2 is present. As indicated by the activity assay presented in figure 16 when 76M D5Q
is present (panel B) the consumption of prethrombin 2/fragment 1·2 and the generation of
the B-chain of thrombin are delayed, while the presence of 100M Hir54-65(SO3-) (panel
C) had no effect on either the consumption of prethrombin 2/fragment 1·2 or the
generation of the B-chain of thrombin. Panels D-F demonstrate that 76M D5Q (panel E)
inhibits prethrombin 2 activation in the presence of cleaved fragment 1·2 (reaction
mixture contained both fragment 1 and fragment 2) at a rate similar to that of
prethrombin 2/fragment 1·2 (panel E), while 100M Hir54-65(SO3-) strongly inhibited
thrombin formation from prethrombin 2 in the presence of both fragment 1 and fragment
2 it showed little inhibition in the activation of prethrombin 2/fragment 1·2. The ability of
the Hir54-65(SO3-) peptide to inhibit the activation of prethrombin 2 was restored upon
cleavage of fragment 1·2.
To directly assay the nonexclusive interaction of the two peptides we next studied
the prethrombin 2 activation in the presence of fragment 1·2 in an activity based assay.
Since the activation of prethrombin 2/fragment 1·2 by prothrombinase was inhibited by
D5Q, but unaffected by Hir54-65(SO3-), if both peptides were interacting at the same site
on the prethrombin 2/fragment 1·2 the Hir54-65(SO3-) would interfere with D5Q ability to
inhibit this reaction. Increasing concentrations of Hir54-65(SO3-) were incubated in the
presence of prethrombin 2/fragment 1·2 followed by titration with D5Q. Figure 18 shows
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Figure 3.18
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Figure 3.18 – DYDYQ titration of prethrombin 2 activation in the presence of
fragment 1·2 and Hir54-65(SO3-). Prethrombin 2 was incubated in the presence of
fragment 1·2 with increasing concentration of Hir54-65(SO3-) and then this ternary
complex was titrated with increasing concentrations of DYDYQ. Results were
standardized to a thrombin standard and graphed nMIIa · min-1 · nMfXa-1 verse the
concentration of DYDYQ.
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that the inhibitory potential of D5Q was not affected by the increased concentrations of
the Hir54-65(SO3-) peptide suggesting a nonexclusive interaction of the two peptides.
3.5 DISCUSSION
A recent study stated that the carboxyl-terminal portion of the heavy chain of fVa
was not involved in recognition of prothrombin, however the study clearly showed that
the removal of this portion of fVa resulted in a 50% loss in the specific activity of the
cofactor which is consistent with several previous studies which demonstrated the
involvement of the carboxyl-terminal portion of the heavy chain of fVa in the recognition
of prothrombin. It has also been suggested that the recognition of prothrombin by fXa is
altered in the presence of fVa due to a prothrombin binding site present on fVa. We have
previous shown that the pentapeptide D5Q inhibited prothrombinase in a competitive
fashion by substrate depletion. In addition we demonstrated that D5Q did not interfere in
the highly specific fVa/fXa interaction. The present study has explored the mode of
inhibition of D5Q on prothrombinase catalyzed activation of all of the physiological
relevant substrates derived from prothrombin.
The present study demonstrated that the interaction of D5Q with prothrombin
resulted in the specific inhibition of cleavage at Arg320 by prothrombinase. Prethrombin 2
in the presence of fragment 1·2 is the naturally occurring intermediate of a membranebound fXa catalyzed activation of prothrombin (pathway 1 in figure 1) and consequently
is a substrate that would naturally occur as a response to an injury, since fXa is generated
before fVa. Therefore prothrombinase would naturally recognize the prethrombin
2/fragment 1·2 intermediate, since the generation of prothrombinase occurs after the
generation of fXa and consequently after some prothrombin has been converted to the
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prethrombin 2/fragment 1·2 intermediate. Interestingly, D5Q was incapable of inhibiting
other naturally occurring derivatives of prothrombin.
Surprisingly, the interaction of D5Q with prothrombin greatly accelerated the
ability of lipid-bound fXa to cleave the zymogen prothrombin at Arg271 to produce the
intermediate prethrombin 2/fragment 1·2. The subsequent activating cleavage at Arg320
by lipid-bound fXa was greatly inhibited due to the interaction of the intermediate with
D5Q resulting in a greatly decreased generation of thrombin by fXa. The interaction of
D5Q with prothrombin or the prethrombin 2/fragment 1·2 intermediates resulted in a
greatly decreased rate of thrombin generation by both prothrombinase and fXa in the
absence of fVa. However D5Q had little inhibitory effect on the activation of other
prothrombin derived fragments or on the activation of prethrombin 2 in the absence of
fragment 1. The prothrombinase catalyzed activation of the intermediates prethrombin 1
or active-site blocked meizothrombin (data not presented) were unaffected by the
presence of D5Q.
Since the carboxyl-terminal region of the heavy chain of fVa shares homology
with the hirudin derived peptides, we initially postulated that D5Q probably interacted
with prothrombin in a fashion similar to the interaction of Hir54-65(SO3-) with prothrombin.
However the present study demonstrates that D5Q and Hir54-65(SO3-) have dissimilar
inhibition patterns and suggests that the interaction of D5Q with prothrombin and the
derivatives of prothrombin occur in a manner independent of the interaction of Hir5465

(SO3-) with prothrombin or the prothrombin derivatives. Further studies directly

identifying the specific binding site of D5Q on prothrombin and its derivatives need to be
performed to establish this, though presently all experimental data imply a distinct
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binding site for D5Q. Finally it is interesting to note that the ability of Hir 54-65(SO3-) to
inhibit the activation of the naturally occurring derivatives of prothrombin demonstrate
almost an exact opposite inhibition pattern as D5Q. While both Hir54-65(SO3-) and D5Q
display strong inhibition on prothrombin, Hir54-65(SO3-) does not reverse the cleavage
pattern observed. Hir54-65(SO3-) strongly inhibit the activation of prethrombin 1, and
prethrombin 2 in the absence of fragment 1·2, while D5Q had little effect in these
reactions. In contrast D5Q strongly inhibited the prothrombinase catalyzed activation of
prethrombin 2 in the presence of fragment 1·2 while Hir54-65(SO3-) showed little ability to
inhibit this reaction.
In conclusion, the present study has demonstrated that a synthetic pentapeptide
derived from the carboxyl-terminal portion of the heavy chain of fVa, strongly inhibits
the activation of prothrombin by both prothrombinase and lipid-bound fXa by selectively
inhibiting the activating cleavage that occurs at Arg320. While D5Q demonstrated little
ability to inhibit the activation of most prothrombin derived intermediates, it did strongly
inhibit the most commonly generated intermediate, prethrombin 2/fragment 1·2. While
the sequence D5Q occurs within a region of fVa that shares homology with the wellestablished anticoagulant peptide molecule derived from hirudin, the interaction between
prothrombin with D5Q or Hir54-65(SO3-) are probably different and result in different
inhibition pattern when the two molecules (i.e. D5Q and Hir54-65(SO3-)) are compared.
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CHAPTER IV
THE AMINO-TERMINAL PORTION OF THE LIGHT CHAIN OF FACTOR Va
INTERACTS WITH FACTOR Xa IN THE PROTHROMBINASE COMPLEX
4.1 ABSTRACT
Prothrombinase assembly occurs when activated factor V (fVa) interacts with activated
factor X (fXa) on a phospholipid bilayer in the presence of divalent metal ions. Previous
studies have shown that the A3 domain from the light chain of fVa contains an interactive
site for fXa which is necessary for proper prothrombinase assembly and function. To
determine which amino acids present within the A3 domain of the light chain of fVa are
involved in recognition of fXa we have used overlapping synthetic peptides
representative of residues 1546-1612 of the A3 domain to screen their ability to inhibit
prothrombinase activity in a fXa dependent manner. The peptide representative of the 13
amino acids spanning residues 1546 through 1558 strongly inhibited prothrombinase
activity demonstrating an IC50 of 50M. To investigate the individual amino acids
involved in recognition of fXa overlapping synthetic pentapeptides from this region were
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used in further flourometeric studies. Peptides which included amino acids representative
of residues 1553-1558 of the A3 domain were capable of inhibited prothrombinase
activity. To further investigate the hypothesis that this region is important in
prothrombinase function a recombinant fV mutant was generated deleting residues 1549 1558 (fVadS13A). The fVadS13A mutant demonstrated a greatly decreased specific activity
in clotting based assays. Prothrombinase assembled with fVadS13A showed a 5 fold
increase in the apparent Kd value for the fVa/fXa interaction and a 50% reduction in the
overall rate of the enzyme. The present study defines a potential fXa interactive site
present within residues 1546-1558 of the A3 domain of fVa.
4.2 INTRODUCTION
The timely repair to vascular injury is dependent on the efficient activation of
thrombin by the enzymatic complex prothrombinase. Prothrombinase is composed of
activated fX, associated with activated fV in the presence of calcium ions on a
phospholipid bilayer (1). The enzymatic component, fXa, is capable of activating the
zymogen prothrombin through two sequential proteolytic cleavages occurring after
residues Arg271 and Arg320 (2). The inclusion of fVa in the prothrombinase complex
reverses the order of these two activating cleavages and accelerates the generation of
thrombin by five orders of magnitude, thus the formation of the prothrombinase complex
is necessary for the timely activation of prothrombin (3-5).
The assembly of the prothrombinase complex is dependent on the activation of
both clotting factors X and V. Activation of fX occurs through a single proteolytic
cleavage catalyzed by either the intrinsic or the extrinsic Xase complexes (6). The
catalytic activity of fXa is not enhanced by the zymogen fV until it has been converted to
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its active form. The activation of fV is catalyzed by either fXa or thrombin and occurs
through three sequential cleavages occurring after residues 709, 1018 and 1545 (7). The
activation of fVa results in the release of an interconnecting B-domain and a fully
functional cofactor molecule composed of by an amino-terminally derived heavy chain
non-covalently associated to a carboxyl-terminally derived light chain (8). The heavy
chain of the fVa is composed of by residues 1-709 and is involved in the recognition of
both fXa and prothrombin, while the light chain is composed of by residues 1546-2196
and is involved in recognition of both fXa and the membrane surface (8-13).
The A3 domain from the light chain of fVa has been implicated many times in
binding fXa. Activity assays performed in the presence of a monoclonal antibody
recognizing an epitope in this region of the light chain showed a decrease interaction
between fVa and fXa (8). A decrease in the ability of fVa to interact with fXa was also
demonstrated by mutagenic studies involving site-directed glycosylation of Thr residues
1683 (14). Another study used the enzymes cathepsin G and elastase to activate fV to a
fVa-like species, both resulted in a cofactor molecule with a truncated heavy chain and an
elongated light chain having a 15 and 8 fold decrease affinity for fXa respectively.
Further treatment of these molecules with thrombin restored a normal light chain and
consequently the affinity for fXa (15). Site directed mutagenesis at Arg1545 showed
similar results demonstrating the necessity of a fully formed light chain as a prerequisite
for an optimal interaction between fVa and fXa (16). Results obtained using an enzyme
from the snake venom of Naja nigricollis nigricollis to activate fV generating a fVa-like
molecule composed of a heavy chain of Mr 100,000kDa and a light chain with a Mr of
80,000kDa displayed a 20 fold increase in the Kd for the fVa/fXa interaction. Further
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cleavage of this molecule with thrombin produced a normal light chain and restored the
affinity of fVa for fXa (17). Taken together all of the above experiments show a strong
dependency of the fVa/fXa association on proper exposure of the A3 domain of the light
chain of fVa.
4.3 EXPERIMENTAL PROCEDURES
Materials, reagents and proteins. L--phosphatidylserine (PS) and L-phosphatidylcholine (PC) were purchased from Avanti Polar Lipids (Alabaster, AL) and
prepared as previously described (18) followed by quantification by assaying for
phosphorus. The chromogenic substrate Spectrozyme-TH was purchased from America
Diagnostica, Inc (Greenwich, CT). Human -thrombin, prothrombin, human fXa and the
fluorescent thrombin inhibitor dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide (Dapa)
were purchased from Hematologic Technologies, Inc. (Essex Junction, VT). The
monoclonal antibody hFV1 coupled to Sepharose, and the two monoclonal antibodies
against factor V (against the heavy and the light chains respectively, HFVHC#17 and
HFVLC#9) were provided by Dr. Kenneth G. Mann (Department of Biochemistry,
University of Vermont, Burlington, VT). Diisopropyl fluorophosphates (DFP), Ophenylenediamine

dihydrochloride

(OPD),

4-(2-hydroxyethyl)-1-

piperazineethanesulfonic acid (HEPES), Trizma, Coomassie Blue R-250 and factor Vdeficient plasma were purchased from Sigma. Polyethylene glycol (Mr 8000) was
purchased from J. T. Baker (Danvers MA). The secondary anti-mouse and anti-sheep IgG
coupled to peroxidase were purchased from Southern Biotechnology Associates Inc.
(Birmingham, AL). The chemiluminescent reagent ECL+ was purchased from Amersham
Biosciences. The thromboplastin reagent (recomboplastin) used in clotting assays was
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purchased from Beckman (Fullerton, CA). The cDNA encoding fV was purchased from
American Type Tissue Collection (ATCC 40515 pMT2-V, Manassas, VA). All
restriction Enzymes were purchased from New England Biolabs (Beverly, MA). Human
fV and fVa were purified and concentrated using methodologies previously described
employing the monoclonal antibody hFV#1 coupled to sepharose and heparin-sepharose
respectively (19-21).
The recombinant fV light chain mutant used throughout this series of experiments
was generated using mutagenic primers. The fV deletion mutant (rfVdS13A) was designed
to remove the amino acids represented by the S13A peptide (The deleted amino acids
were

residues

1549-1558)

and

was

generated

using

the

primers

5'GCAGCATGGTACCTCCGCAGCAACAATGAAGAAATATCCTGGGATTATTCA
G-3'

and

5'-CTGAATAATCCCAGGATATTTCTTCATTGTTGCTGC-

GGAGGTACCATGCTGC-3'. These mutagenic primers were used in PCR employing
pMT2-fV plasmid as a template and the product was subjected to DpnI digestion before
transformation into chemically competent bacteria. Colonies were selected and purified
plasmids were screened for the presence of the desired mutation by DNA sequencing.
Purification and Determination of Concentration of rfV Mutants – The
recombinant proteins were generated as previously described (22). Cultured VP-SFM
medium of WT and rfVadS13A concentrated using a vivaflow 50 connected to a masterflex
L/S to a final volume of approximately 10ml followed by washing with a trizma (20mM
trizma base) buffered saline solution with 5mM Ca2+ at pH 7.40. Purification was
performed on 1 ml columns of HFV-1 antibody coupled to sepharose and eluted using
2M NH3Cl at a pH 7.40 and concentration by centrifugation on YM-30 centricons
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followed by three consecutive washes with trizma buffered saline solution in the presence
of 5mM CaCl2. Aliquots of purified protein were stored at -80°C for future use. Protein
concentration were determined using spectrophotemetry and an extension coefficient of
0.96 (1%280nm) followed by ELISA (as previously described) to independently confirm
the concentration (22). Protein purity was determined by coomassie and silver staining of
SDS-PAGE.
Activation of Recombinant Molecules – Throughout the present study activation
of all recombinant fV molecules was accomplished by incubation of the purified
molecules with thrombin at a 1/100 (enzyme to substrate) ratio for ten minutes at 37°C.
Addition of 2mM DFP, a specific serine protease inhibitor, stopped the reaction, followed
by a 30 minute incubation on ice. Previous experiments showed that these conditions
assure complete activation of the cofactor with minimal thrombin degradation to the
activated molecule. However in all cases western blots using monospecific antibodies
that recognize the heavy and light chains respectively was performed to assure minimal
degradation of the activated protein.
Determining the Kinetic Parameters Governing Mutant Molecules – Assays
measuring the kinetic parameters consisted of prothrombinase assembled in the presence
of prothrombin and measured the appearance of the product thrombin by the secondary
event of cleavage of a chromogenic substrate. This is a discontinuous assay measuring
the initial velocity of the reaction through monitoring several time points within the first
two minute of the reaction. The determination of the affinity of fVa for fXa was
measured directly through titrating a limiting fXa concentration with increasing
concentrations of fVa to determine the apparent Kd value for the fXa/fVa interaction.
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Assays were performed in 96 well plates and measured the initial velocities of product
formation from the different concentrations of the titrant (fVa). Time points from each of
the different reactions were stopped by addition into a buffer containing EDTA. Prism
graphing software was used to interpret the data and generate kd values for the titrations.
In all cases mutants were compared to wild type protein and measurements were done in
triplicate with different protein purifications. The obtained kd values were used to
determine proper ratios of fVa mutants to fXa to ensure similar concentrations of the
assembled prothrombinase complex to be used in the prothrombin titrations. Prothrombin
titrations were performed to determine the apparent km values for prothrombinase
assembled with rfVadS13A. Prothrombin titrations were performed in 96 well plates and
reactions consisted of a limiting fXa concentration in the presence of saturating fVa
concentrations as determined by kd values obtained from the fVa titrations. Prism
graphing software was used to determine measurements of the initial velocity of the
varied prothrombin concentrations and to generate a secondary graph measuring
maximum velocity and km of the various reactions.
Effects of Mutant Molecules in Prothrombin Activation. – Since prothrombin
activation consists of two ordered sequential cleavages resulting in intermediates with
enzymatic activity, meizothrombin, and without enzymatic activity, prethrombin 2,
deficiency in assays measuring thrombin formation monitored through a chromogenic
substrate may not show the reason for the deficiency. Monitoring prothrombin
consumption

using

SDS

PAGE

allows

determination

of

cleavage

patterns.

Prothrombinase assembled with rfVadS13A were used in prothrombin activating reactions
subjected to SDS-PAGE followed by coomassie blue staining. Aliquots of reaction
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mixtures were placed in 0.2M acetic acid to stop the reaction followed by preparation for
SDS-PAGE as previously described (23).
Clotting Times Measurements – One stage and two stage measurements of time to
clot formation were performed with identical concentrations of all the fVa molecules
used throughout this study. One-stage clotting assay were performed by the addition of
the procofactor (fV) into fV deficient plasma, while two stage clotting assays were
performed with the activated cofactor (fVa) being added to fV-deficient plasma. In both
cases coagulation was initiated by the addition of thromboplastin reagent and the time to
clot formation measured. Recombinant molecules unable to accelerate fibrin clot
formation in fV-deficient plasma to the same degree as wild type fVa are considered to
be functionally defective. All purified protein preparations were assayed in triplicate in
this manner.
Fluorescence Measurements of Thrombin Generation – Thrombin formation was
analyzed using the fluorescent inhibitor DAPA on a PerkinElmer LS-50B Luminescence
spectrophotometer. Reactions were performed in the presence and absence of the various
peptides by incubating a final concentration of 10nM fXa with the various concentrations
of the different peptides for ten minutes at ambient temperature before addition into
reactions mixture composed of 4nM fVa, 20M PCPS, 350nM prothrombin in a HEPES
buffered saline solution. Reactions were monitored using an excitation wavelength at
280nm and an emission wavelength of 520nm. All reactions performed in the presence of
peptides were compared to reactions performed in the absence of peptides to measure the
percent inhibition.
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4.4 RESULTS
Since previous studies demonstrated the possibility that the interaction of fXa
with the light chain of fVa involved the amino-terminal region of the A3 domain (8,1417), initial studies were performed using overlapping synthetic decapeptides
representative of the A3 domain sequence to screen their ability to inhibit prothrombinase
activity. Figure 1 shows a schematic of the synthetic peptides used throughout this study
with reference to the sequence they represent and their chosen nomenclature.
Fluoremetric analysis of thrombin generation by prothrombinase in the presence of the
various peptides is presented in figure 2 and shows only two of the screened peptides
significantly inhibited thrombin generation. Both S13A and LCD3, peptides
representative of residues 1546-1558 and 1569-1578 respectively, inhibited thrombin
generation by prothrombinase in a manner similar to the activity of fXa alone, implying a
possible diminished interaction between fXa and fVa. S13A was the stronger of the two
inhibitory peptides and is representative of the amino-terminal region of the light chain of
fVa, a region conserved through evolution as shown in figure 3. All of the other peptides
from this region had little to no inhibitory effect on the activation of prothrombin by
prothrombinase.
Since S13A showed the strongest inhibition in the initial screening of this region,
we next designed a series of overlapping pentapeptides from the sequence of S13A.
Figure 4 is a schematic showing the next series of peptides used throughout this study
with their sequence compared to that of S13A and their assigned nomenclature on the
right of their sequence. A follow up fluoremetric study presented in figure 5
demonstrated only the latter three of these five pentapeptides had any inhibitory
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Figure 4.1
1546

SNNGNRRNYYIAAEEISWDYSEFVQRETDIEDSDDIPEDTTYKKVVFRKYLDSTFTKRDPRGEYEEH

1612

S13A SNNGNRRNYYIAA
EEISWDYSEF
LC1
LC2
DYSEFVQRET
LC3
VQRETDIEDS
LC4
DIEDSDDIPE
LC5
DDIPEDTTYK
LC6
DTTYKKVVFR
LC7
KVVFRKYLDS
LC8
LC9
KYLDSTFTKR
LC10
TFTKRDPRGE
DPRGEYEEH

Figure 4.1 – Synthetic peptides generated for screening light chain’s ability to
associate with fXa. Figure 1 shows a schematic of the synthetic peptides used
throughout this study. The corresponding sequence of the light chain of fVa is
presented at the top of the figure along with the corresponding residue numbers. The
nomenclature used throughout the study for these peptides are presented at the leftside of the schematic, while the actual sequences are shown under the sequence from
the light chain of fVa they represent.

114

Figure 4.2

 LC Peptides
100

110

100

90

80

70

60

50

40

30

20

10

0

Xa/Va

Xa

P15H

LC1

LC2

LC3

LC4

LC5

LC6

LC7

LC8

LC9

LC10

LC11

LC12

Figure 4.2 – The synthetic peptides abilities to inhibit prothrombinase. The synthetic
peptides introduced in figure 1 were incubated with 10nM fXa before addition into a
reaction mixture composed of 4nM fVa, 20M PCPS, 10M Dapa and 350nM
prothrombin. Reactions were monitored through fluorescence as described in the
experimental procedures section. Figure 2 shows the control reactions catalyzed by the
prothrombinase complex and lipid-bound fXa followed by reactions catalyzed by
prothrombinase assembled in the presence of the 100M of respective peptides.
Reactions performed in the presence of the various peptides were compared to
reactions performed in the absence of peptide as a means of calculating percent
control.
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Figure 4.3

HUMAN
BOVINE
MOUSE
PORCINE

SNN GNR RN YY IAA
SNT GNR KY YY IAA
GHG GHK KF YY IAA
SNN GNR RN YY IAA

Figure 4.3 – A comparison of the amino-terminal sequence of the light chain of
fVa from different species. The sequence of the region represented by the S13A
peptide from bovine, mouse and porcine is compared to the human sequence and
demonstrates strong homology.
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Figure 4.4

SNNGNRRNYYIAA
SNNGNRR
NYYIAA
NFFIAA

S13A
S7R
N6A
N6A (FF)

SNNGN
NGNRR
NRRNY
RNYYI
YYIAA

S5N
N5R
N5Y
R5I
Y5A

Figure 4.4 – Synthetic peptides used in determining the binding site present
within the light chain of fVa for fXa. Schematic showing the peptides used for the
determination of the binding site present within the light chain of fVa for fXa. S13A is
a synthetic peptide which strongly inhibits thrombin generation in a prothrombinase
catalyzed reaction that is representative of the amino-terminal region of the light chain
of fVa (residues 1546 – 1558). All other peptides used are shorter derivatives of S13A
and are aligned under the sequence for S13A.
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Figure 4.5
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Figure 4.5 – Inhibition study using overlapping pentapeptides representative of
the amino-terminal region of the light chain of fVa. Overlapping pentapeptides
representative of amino acid residues 1546 – 1558 of the light chain of fVa were
synthesized to screen their ability to inhibit thrombin activation by prothrombinase.
Reaction mixtures consisting of 4nM fVa, 700nM DAPA, 10M PCPS and 350 nM
prothrombin were initiated with 10nM fXa (final concentration in the reaction) that
was incubated for 10 minutes in the presence of 150M of the respective peptides as
indicated in the figure. Initial velocities were measured throughout the first 30 seconds
of the reaction and compared to a standard reaction performed in the absence of
peptide to determine the percent inhibition. All reactions were performed in triplicate
and error bars are representative of standard deviation.
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ability on thrombin generation by prothrombinase. The three pentapeptides N5Y, R5I and
Y5A all showed the ability to inhibit thrombin generation with Y5A being the strongest
inhibitor of the series of overlapping S13A derived peptides. Y5A demonstrated an IC50
of 150M and shows 100% conservation of the compared sequences presented in figure 3.
Since peptide inhibition of prothrombinase only occurred when amino acids
representative of residues 1553-1558 were used and no inhibition was observed with
peptide sequences representative of amino acids 1546-1552, two additional peptides were
generated from the S13A sequence. As shown in figure 4 the two peptides representative
of amino acids 1546-1552 and 1553-1558 were S7R and N6A respectively. When S7R
and N6A were titrated into a prothrombinase catalyzed activation of prothrombin and
monitored by fluoremeter, N6A displayed a similar inhibition pattern as compared to
S13A. This suggested that the amino acid sequence from 1553-1558 was involved in the
observed inhibition, so this sequence was then altered as a control for the specificity of
this sequence. The charge of the pentapeptide was weakened by the removal of the
charges from two amino acids, two tyrosine residues were conservatively substituted to
phenylalanines as depicted in figure 4. The N6A(FF) peptide lost the inhibitory effect
demonstrated by the unaltered sequence of the N6A peptide as shown in figure 6 (opened
triangles).
Since all of the peptide studies suggested that the amino-terminal region of the
light chain of fVa was involved in the recognition of fXa, we next studied the possibility
that this region of fVa was involved in fXa recognition through recombinant methods. A
recombinant molecule deleting the region represented by the S13A peptide was generated
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Figure 4.6
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Figure 4.6 – Titration of S13A, S7R, N6A(WT) and N6A(FF) in a
prothrombinase catalyzed activation of prothrombin. Increasing concentrations of
the synthetic peptides S13A, S7R, N6A(WT) and N6A(FF) were incubated in the
presence of 10nM fXa for 10 minutes before addition into a reaction mixture
composed of 4nM fVa, 700nM DAPA, 10M PCPS, and 350nM prothrombin.
Reactions were monitored through the fluorescence properties of DAPA and
compared to standards performed in the absence of peptides to determine the percent
inhibition. All reactions were performed in triplicate and error bars are representative
of standard deviation.
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as described in the material and method section. The recombinant fVa molecule missing
residues 1546-1558 (rfVadS13A) was activated by incubation with thrombin and subjected
to SDS PAGE followed by Western blotting. Figure 7 shows a Western blot using
monoclonal antibodies which recognizing the heavy and light chains of rfVadS13A and
rfVaWT. Upon activation both the rfVadS13A and rfVaWT molecules generated the heavy
and light chains of the active cofactor, however the rfVadS13A molecule always produced
a fragment present at 220,000kDa that persisted even after extended incubation with
thrombin.
We next studied the ability of prothrombinase assembled with the rfVadS13A
molecule to activate prothrombin and monitored the reaction through SDS PAGE as
presented in figure 8. When reactions catalyzed by prothrombinase assembled with the
rfVadS13A (panel B) are compared to reactions catalyzed by prothrombinase assembled
with plasma derived fVa (panel A) an approximately 50% reduction in the ability to
activate prothrombin is observed. When the impaired function of prothrombinase
assembled with the rfVadS13A molecule is directly compared to the inhibition of the S13A
peptide on prothrombinase assembled with fVa (panel C) similar rates are observed.
Densitometry scanning of the SDS PAGE presented in figure 8 was performed to produce
the rates of prothrombin consumption presented in table 1. As shown, the rate of
prothrombin consumption in the presence of saturating concentrations of S13A, 4.5
moles consumed·s-1·mole of fXa-1, was comparable to the rate of prothrombin
consumption by prothrombinase assembled with the recombinant fVadS13A molecule, 5.7
moles consumed·s-1·mole of fXa-1.
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Figure 4.7

rfVaWT

rfVadS13A

220,000kDa

Heavy Chain

Light Chain

Figure 4.7 – Western blot of recombinant molecules. The monoclonal antibodies
hfV#9 and hfV#17 were used to detect both the heavy and light chains of the
rfVaWT and rfVadS13A molecules. The positions of both the heavy and light chains of
fVa are indicated along with a partial activation fragment present in the rfVadS13A
sample
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Figure 4.8
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Figure 4.8 – SDS PAGE analysis of prothrombinase catalyzed activation of
prothrombin in the absence and presence of S13A and prothrombinase
assembled with rfVadS13A. Panels A-C are prothrombinase catalyzed reactions that
were performed under the following conditions: 10nM fVa species (panel A used
rfVa, panel B used rfVadS13A and panel C used plasma derived fVa in the presence of
100M S13A), 0.5nM fXa, 10M DAPA, 20M PCPS and 1.4M prothrombin.
Reactions were initiated by the addition of fXa and aliquots were removed for SDS
PAGE before the addition of fXa and 20, 40, 60, 80, 100, 120, 140, 160, 180, 200,
220, 240, 300, 360, 600, 1200, 1800 and 2400 seconds after the addition of fXa.
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Table 4.1
Moles consumed·s-1·mole of fXa-1
WT

fVadS13A

fVa + S13A

12.6

5.7

4.5

Table 4.1 – Densitometry scanning of SDS PAGE presented in figure 8.
Densitometry scans for the three SDS PAGE presented in figure 8 were performed to
determine the rate of prothrombin consumption by prothrombinase assembled with the
rfVadS13A mutant and prothrombinase in the presence of 100M S13A. Scanning of the
control reaction of prothrombinase assembled with rfVaWT was also performed as a
control. The rates shown are moles of prothrombin consumed per second per mole of
fXa present in the reaction.

125

To explore the possibility that the inhibition pattern observed in figure 8 is due to
a decrease affinity of rfVadS13A for fXa, a limiting concentration of fXa was titrated
against an increasing concentration of the rfVadS13A mutant. Figure 9 shows the graph
generated when the rfVa molecules were titrated against 15pM fXa. The titrations was
carried out to 20nM rfVa concentrations, however the graph only shows the titrations to
10nM. As shown, both titrations were carried out until increasing the concentration of the
different recombinant cofactor molecules no longer significantly increased the rate of
thrombin production over the previous concentrations implying a maximum rate of
thrombin production had been obtained. The determined apparent Kd values obtained
from the fVa titrations are presented in table 2. The rfVadS13A apparent Kd value of 1.915
is 5.5 times higher than the rfVaWT apparent Kd value suggesting a greatly weakened
interaction between the rfVadS13A and fXa when compared to the rfVaWT affinity for fXa.
The rfVadS13A apparent Kd value was used to determine the saturating
concentration of rfVadS13A used in the prothrombin titration presented in figure 10. A
concentration of 20nM rfVadS13A was used to ensure that more than 95% of the fXa in
solution was associated with the rfVadS13A molecule for the prothrombin titration. This
allowed the determination of apparent Km and Kcat values for prothrombinase assembled
with the rfVadS13A, because the concentration of the enzymatic complex formed rather
than the concentration of the constituents of the enzymatic complex were measured.
Figure 10 presents the graphs generated from the prothrombin titration of prothrombinase
assembled with the rfVaWT and the rfVadS13A cofactor molecules respectively. Initial rates
of thrombin formation over the various prothrombin concentrations used in the reactions
were graphed to determine the maximum velocity of the respective enzymes. Table 2
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Figure 4.9
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Figure 4.9 – fVa titration with prothrombinase assembled with rfVaWT and
rfVadS13A. The determination of the kd values for the rfVadS13A was performed through
titrating increasing concentrations of rfVadS13A into a prothrombinase catalyzed
activation of prothrombin. Reaction conditions used were: 0.015nM fXa, 10M
DAPA, 20M PCPS and 1.4M prothrombin. Titrations were performed in triplicate
using different protein preparations and compared to titrations performed using
rfVaWT. Error bars are representative of standard deviation. The empirically derived kd
values are presented in table 2.
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Figure 4.10
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Figure 4.10 – Prothrombin titrations performed in the presence of fully saturated
prothrombinase assembled with rfVaWT and rfVadS13A. The determination of the
kinetic parameters governing rfVadS13A was performed through titrating fully
complexed prothrombinase assembled with rfVadS13A with increasing concentrations
of prothrombin. Reactions conditions for the titrations were: 0.5pM fXa, 10M
DAPA, 20M PCPS and 20nM rfVadS13A for the prothrombinase assembled with
rfVadS13A and 10nM rfVaWT for the prothrombinase assembled with the wild type
cofactor. Initial velocities were monitored through the chromogenic substrate S-2238
and compared to a thrombin standard for quantification. The empirically derived
kinetic values are presented in table 2.
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Table 4.2
Kd
(nM)

Km
(M)

Kcat
(min-1)

0.3500

0.2681

2002

1.915

0.3724

1136

rfVaWT
dS13A

rfVa

Table 4.2 – The apparent kinetic constants as derived from the titrations
presented in figures 9-10. The titrations presented in figures 9 and 10 were analyzed
using Prisma 2.01 Graphing software to generate the kinetic values presented in table
2.
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shows the apparent Km and Kcat values generated from the prothrombin titration
presented in figure 10. The apparent Km value was not significantly altered when
prothrombinase was assembled with the rfVadS13A as compared to prothrombinase
assembled with rfVaWT, as evident by the respective values; 0.3724M and 0.2681M.
However the Kcat of the reaction for the prothrombinase assembled with rfVadS13A was
50% reduced, demonstrating that the weakened interaction of the rfVadS13A/fXa complex
resulted in a defective enzymatic complex which could not be corrected for by increasing
the concentration of the rfVadS13A molecule.
4.5 DISCUSSION
The present study strongly suggests, through synthetic peptide analysis and
recombinant mutagenesis, that amino acid residues 1546-1558 from the light chain of fVa
are crucial for fXa recognition and thus prothrombinase assembly. The synthetic peptide
S13A, representative of residues 1546-1558 strongly inhibited prothrombinase ability to
generate thrombin. The use of overlapping synthetic peptides from this region
demonstrated that the amino acid sequence representative of residues 1553-1558 were the
main contributors of the inhibition of S13A on prothrombinase. This was confirmed by
the fact that N6A had the same inhibition profile as S13A. Further, when the charged
residues present within this region were exchanged for amino acids lacking charge (i.e.
tyrosine residues exchanged for phenylalanine residues), in essence removal of the charge,
the ability of N6A to inhibit prothrombinase function was lost, suggesting the
involvement of the two tyrosine residues present at positions 1554 and 1555. While all of
the peptide studies generated consistent results, the major weakness of the peptide portion
of the present study is the specificity of peptides and whether the observed inhibition is
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due to the weakened interaction of the highly specific fVa/fXa association as opposed to
a nonspecific inhibition.
To ascertain whether the indicated region from the peptide study was involved in
the fVa mediated assembly of the prothrombinase complex a recombinant study
employing a fV mutant deleting the indicated region was undertaken. The rfVadS13A
mutant was directly assayed for its ability to recognize fXa and the measurements of the
interaction for the rfVadS13A with fXa demonstrated a greatly weakened association
between the two proteins when compared to the rfVaWT/fXa interaction. This strongly
suggests that the loss of the ability of the rfVadS13A molecule to recognize fXa with the
same affinity as rfVaWT is due to the loss of a major binding site present within the
deleted region. When fXa is fully saturated with the rfVadS13A mutant a reduced Kcat is
observed, this is consistent with a previously observed phenomenon using recombinant
fVa mutants with a diminished ability to recognize fXa (23). As previously shown, the
ability of fVa to optimally promote catalysis through fXa is dependent on the proper
association between several points of contact between the two proteins and the lowered
Kcat generated from prothrombinase assembled with the rfVadS13A mutant is consistent
with this previously observed phenomenon (23).
A major concern for the recombinant portion of this study is the accuracy of the
determined concentration of the rfVadS13A molecule. If the determined concentration of
the rfVadS13A mutant is elevated over the true concentration, then the determined KD
would also be elevated and the generated results would be skewed. However, this would
not account for the decreased ability of the rfVadS13A cofactor to promote the generation
of thrombin when assembled into the prothrombinase complex, since the apparent KD
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values enabled the determination of the concentration of the cofactor molecule needed to
fully saturate fXa. Another concern with the recombinant portion of this study is a
concern that any recombinant study has being the possibility that the induced mutation
had a detrimental effect on the confirmation of the protein. Though rfVadS13A generated a
light chain upon thrombin incubation comparable to that of the rfVaWT, a persistent
activation fragment around 220,000kDa persisted and appeared to be resistant to
thrombin cleavage. However, even though detectable concentrations of the light chain
were always generated, the function of the rfVadS13A cofactor molecule could not be
restored by increasing the concentration, suggesting that the decreased cofactor activity
observed in the rfVadS13A was due to the loss of an interactive site for fXa.
Since the characterization of the recombinant deletion molecule displayed an
impaired function resulting from a weakened interaction with fXa, the hypothesis that a
major binding site is present within the deleted portion of rfVadS13A is greatly
strengthened. Coupled with the fact that both the peptide study and the recombinant study
suggested the same region of the light chain of fVa was involved in the recognition of
fXa also strongly supports the hypothesis. The amino-terminal portion of the light chain
of fVa has an extremely conserved sequence across species with the sequence of the 13
amino acids represented by S13A showing strong conservation. The high degree of
conservation of this region suggests an important function present within this region and
coupled with previous observations of the light chains involvement in the recognition of
fXa, further strengthens the hypothesis that this region is involved in recognition of fXa.
In conclusion, the present study strongly suggests that the amino-terminal portion
of the light chain of fVa is involved in the association with fXa and that the loss of this
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interactive site results in a decreased ability of prothrombinase to generate thrombin in an
efficient manner. Further, the involvement of amino acid residues 1546-1558 in the
recognition of fXa is a prerequisite for the association of fVa with fXa and consequently
these residues are necessary for proper prothrombinase assembly.
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CHAPTER V
OVERALL CONCLUSIONS
5.1 CONCLUSION
The assembly of prothrombinase is crucial for the function of prothrombinase; the
two events are interconnected and cannot be separated from each other. The contribution
of fVa to the assembly/function of the prothrombinase complex is essential; since it is
involved in recognizing all of the components of prothrombinase. Hence fVa can be
considered the driving force behind prothrombinase complex formation and function. The
interaction of fVa with all of the components of prothrombinase is the accelerating event
in the activation of prothrombin which results in the rapid generation of thrombin through
formation of the enzymatic intermediate, meizothrombin (1,2). Prothrombinase consists
of an assembly of the two activated clotting factors (i.e., fXa and fVa) in the presence of
divalent metal ions on an activated platelet surface (3). The association between fVa and
fXa has been shown to involve two distal portions of fVa, involving residues present
within the A2 domain of the heavy chain and A3 domain of the light chain (4).
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Previous studies have demonstrated that the association between fVa and fXa is
partially mediated through the region encompassing residues 307-348 present within the
heavy chain of fVa (5). Presently we have shown that this interaction between the A2
domain of the heavy chain of fVa and fXa is mediated through four distinct amino acid
residues; Asp323, Tyr324, Asp330 and Val331. Recombinant technologies were used to
induce site-specific mutations present within these residues to assay their contribution to
the activity of prothrombinase. The data demonstrated that the removal of either binding
sites present on fVa (i.e., 323DY324 or 330DV331) for fXa resulted in a decreased KD for the
interaction between the two proteins with little effect on the Kcat for prothrombinase
assembled with fVa mutated at either of the two binding sites. When the induced
mutations for both of the discrete binding sites present within the heavy chain of fVa
were combined into the same recombinant protein, a normal Kcat value could not be
restored when assembled into prothrombinase. This demonstrates that the optimal
interaction between fVa and fXa is a prerequisite for the catalytic efficiency normally
displayed by prothrombinase (6,7).
It has been demonstrated on several occasions that the interaction of fVa with fXa
involves the light chain of the activated cofactor (8-11). Screening overlapping synthetic
peptides representative of sequences present within the light chain of fVa for their ability
to inhibit the prothrombinase catalyzed activation of prothrombin demonstrated that the
peptide representative of the first thirteen amino acids present at the beginning of the
light chain of fVa was the strongest inhibitor of prothrombinase. The recombinant follow
up study demonstrated that the removal of this region from the light chain of fVa resulted
in a diminished association with fXa and when the deletion protein was assembled into
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prothrombinase, the enzymatic complex displayed a 50% reduction in its ability to
activate prothrombin. Demonstrating again that for prothrombinase to achieve optimal
catalytic efficiency the unhindered interaction between fVa and fXa is necessary.
Prothrombinase recognizes prothrombin in a fashion different than membranebound fXa. Several studies have demonstrated that the carboxyl-terminal portion of the
heavy chain of fVa is involved in the recognition of prothrombin by prothrombinase (1215). We have previously shown that residues

695

DYDYQ699 from the heavy chain of fVa

are crucial for optimal prothrombinase activity and have also demonstrated that a
synthetic peptide representative of these residues strongly inhibited thrombin generation
by prothrombinase in a manner consistent with substrate depletion (16). Presently we
have explored the ability of lipid-bound fXa and prothrombinase to activate prothrombin
and derivatives of prothrombin in the presence of the pentapeptide D5Q. We have seen
the association of D5Q with prothrombin causes a switch in the pathway to thrombin
generation by prothrombinase and greatly delays thrombin generation by lipid-bound fXa
by inhibiting the activation of the prethrombin 2/fragment 1·2 intermediate (17). In both
cases the interaction of D5Q with prothrombin specifically inhibited the activating
cleavage at Arg320 and resulted in a greatly delayed generation of thrombin. Interestingly,
D5Q was incapable of significantly inhibiting the activation of any of the other
prothrombin derived substrates tested throughout this study suggesting the selective
nature of the observed inhibition (18).
The optimal catalytic efficiency of prothrombinase can only be realized when fVa
is properly associated with fXa. This is because the accelerated enzymatic capability of
fXa is dependent on the association with fVa through residues present in both the heavy
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and light chains of fVa. We have shown that the association between fVa and fXa involve
residues

323

DY324 and

330

DV331 from the A2 domain of the heavy chain of fVa and also

involves amino acids present within residues 1546 through 1558 of the A3 domain (6).
While the residues 323DY324 and 330DV331 and the region from residues 1546 through 1558
are important for proper assembly of prothrombinase, the carboxyl terminal portion of the
heavy chain of fVa is necessary for prothrombinase to properly recognize prothrombin
(16). It has been demonstrated that a loss of the carboxyl terminal portion of the heavy
chain of fVa results in a cofactor with reduced activity when assembled into
prothrombinase (19). Further, a pentapeptide from this region, DYDYQ, greatly inhibits
the activation of prothrombin by prothrombinase in a fashion consistent with substrate
depletion, suggesting that the sequence 695DYDYQ699 directly interacts with the substrate,
prothrombin (16).
Since all of the above mentioned regions are crucial for prothrombinase assembly
and consequently prothrombinase function, they represent possible targets for inhibiting
prothrombinase. Prothrombinase function may be stopped through interrupting its
assembly, since prothrombinase assembly is a prerequisite for its proper function.
Through defining major points of interaction between the components of prothrombinase
novel therapeutic targets are defined that can specifically interfere with the assembly of
prothrombinase. Therefore, inhibitory synthetic peptides derived from amino acid
sequences present within fVa, not only illuminate the molecular functions of
prothrombinase but may represent a backbone on which to design potential therapeutic
agents which will specifically target prothrombinase.
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